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Cervical cancer (CC) is a common cancer in women. Oncogenic human 
papillomavirus (HPV) types are the necessary etiological agents of CC.
Results from a population-based Nordic joint cohort study showed that tobacco 
smoking was associated with an increased risk of CC and squamous cell 
carcinoma (SCC) after adjustment to oncogenic HPVs. A statistically significant 
2-fold excess risk of SCC was found among HPV16/18-seropositive women who 
smoked. 
A cross-sectional study conducted in Côte d’Ivoire and Finland revealed that 
young women who smoked tended to have an increased risk of high-grade SIL 
(HSIL). Relative to non-chewers, women who chewed tobacco had a significantly 
5-fold increased risk of cervical HSIL. 
In addition, the results suggest that smoking may induce impaired antibody 
response to oncogenic HPVs but not immediately after prophylactic HPV 
vaccination in young women. 
The evidence discussed in this dissertation supports comprehensive primary 
prevention initiatives against causes of CC, with a call for strengthening efforts 
to prevent tobacco smoking and chewing exposures among women. 
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Abstract
Aline Simen-Kapeu. Epidemiological Study of Tobacco Use and Human 
Papillomavirus – Implications for Public Health Prevention. National Institute for 
Health and Welfare (THL), Research 20. 150 pages. Helsinki 2009. 
ISBN 978-952-245-126-2 (printed), ISBN 978-952-245-127-9 (pdf)
Cervical cancer (CC) is one of the most common forms of cancer in women. 
The sexually transmitted oncogenic human papillomavirus (HPV) types are the 
necessary etiological agents of CC. However, only a small fraction of HPV-infected 
women go on to develop cancer. Other avoidable co-factors that act in conjunction 
with HPV to promote cervical malignant lesions need to be verified and tackled. 
Tobacco exposure, a potential environmental cofactor of CC, has attracted 
increasing attention since the early 1980s. 
My aim in this thesis was to assess the role of tobacco exposure in cervical 
precancerous lesions and cancer of the uterine cervix as well as in multiple HPV 
infections, and to evaluate the impact of tobacco smoking on the immune response 
to natural HPV infection as well as to HPV vaccination. 
A population-based case-control study of CC was nested within a joint cohort 
of five Nordic serum banks from Finland, Iceland, Norway and Sweden. The 
samples of cases and controls were analyzed for cotinine (a biomarker of tobacco 
smoking) and antibodies to HPV types 16 and 18, herpes simplex virus type 2 
(HSV-2), and Chlamydia trachomatis (C. trachomatis). Due to small sample size, 
the first study material (171 cases and 496 controls) (Paper I) had limited power 
to distinguish whether tobacco smoking was an independent cofactor in cervical 
carcinogenesis or whether its relative role was due to residual confounding by the 
oncogenic HPVs. In the second study material (Paper I), we assembled almost 
four times bigger independent material, including 588 cases and 2,861 controls. 
We identified smoking as an independent risk factor for CC. A highly significant 
2- to 3-fold increased risk of invasive CC (Odds ratio (OR) = 2.1; 95% confidence 
interval (CI): 1.4–3.2) and squamous cell carcinoma (SCC) (OR = 2.7; 95% CI: 1.7–
4.3), free of residual confounding bias, was found among HPV16/18-seropositive 
heavy smokers. In addition, the point estimates increased with increasing age at 
diagnosis (probably indicating longer exposure) and increasing cotinine level.
In a cross-sectional analysis (Paper II), we compared the association between 
tobacco smoking and chewing and the risk of multiple HPV infections and cervical 
squamous intraepithelial lesions (SILs) in two populations with different routes 
of tobacco exposure. We studied 2,162 women from Côte d’Ivoire, West Africa, 
and 419 women from Finland, Northern Europe, with baseline data on cervical 
screening, smoking and chewing habits, HPV DNA status, C. trachomatis status 
and human immunodeficiency virus (HIV) seropositivity. In both settings, tobacco 
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consumers (chewers or smokers) ≥30 years of age tended to have an increased risk 
of low-grade SIL (LSIL). Among tobacco chewers (Côte d’Ivoire), the risk of high 
grade SIL (HSIL) was five times higher in both young (OR = 5.5, 95% CI: 1.2–
26) and older (OR = 5.5, 95% CI: 2.1–14) women compared to non-chewers. We 
found an increased, albeit not significant, risk of both LSIL and HSIL, in HPV-
DNA positive women ≥30 years of age and actively exposed to tobacco through 
smoking or chewing. There was no increased risk of multiple HPV infections 
among tobacco consumers.
In a cohort study (Paper III), we evaluated the association between humoral 
immune response to HPV and smoking in 191 HPV infected women prospectively 
followed-up for 10 years by cytology and HPV DNA analyses. The baseline 
sample and the last follow-up sample were analysed for serum cotinine levels, 
Immunoglobulin (Ig) A and IgG antibodies to HPV16 and 18, and C. trachomatis 
using ELISA methods. Young women (<30 years of age) who smoked were less 
likely to either seroconvert or maintain detectable HPV16/18 antibodies over 
the follow-up time (up to 10 years) than non-smokers. This suggests that among 
young women with oncogenic HPV16/18 infections, smoking impairs the humoral 
immune response to high-risk HPV types.
A phase III double-blind, randomized controlled trial enrolled 4,808 16- to 
17-year-old females in Finland to receive either the prophylactic HPV16/18 AS04-
adjuvanted vaccine-like-particle (VLP) vaccine or hepatitis A vaccine (HavrixTM) 
as a control (Paper IV). We conducted a pilot study among 216 participants to 
compare HPV16/18 antibody levels of nonsmokers and smokers 7 months post-
vaccination (one month post the third vaccination dose). Baseline and month 7 
serum samples were analysed for cotinine levels and IgG antibodies to HPV16 and 
18. We found that women who smoked appeared to have comparable levels of anti-
HPV16 and 18 antibodies to nonsmokers at month 7 post-vaccination. Our data 
suggest that smoking may not have an impact on the humoral antibody response 
following HPV vaccination.
Alongside the development and combination of HPV vaccination 
programmes and screening and early diagnosis of CC, our findings support public 
health initiatives intended to prevent tobacco smoking and chewing exposures, 
particularly among young women.
Keywords: human papillomavirus, seroepidemiology, tobacco smoking, tobacco 
chewing, immune response, fertile-aged women, HPV vaccine, cervical cancer 
prevention
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Abstract in Finnish
Aline Simen-Kapeu. Epidemiological Study of Tobacco Use and Human 
Papillomavirus – Implications for Public Health Prevention [Epidemiologinen tut-
kimus tupakoinnista ja ihmisen papilloomaviruksesta – merkitys kansanterveys-
työlle]. Terveyden ja hyvinvoinnin laitos (THL), Tutkimus 20. 150 sivua. Helsinki 
2009. ISBN 978-952-245-126-2 (painettu), ISBN 978-952-245-127-9 (pdf)
Kohdunkaulan syöpä on yksi naisten yleisimmistä syöpämuodoista. Seksin yhtey-
dessä tarttuvat syöpävaaralliset ihmisen papilloomavirukset (HPV) ovat kohdun-
kaulansyövän välttämättömiä syytekijöitä. Vain pieni osa HPV-infektioon sairastu-
neista naisista saa syövän. Muut vältettävissä olevat osatekijät, jotka saavat yhdessä 
HPV:n kanssa kohdunkaulansyövän esiasteet etenemään on identifioitava ja voitet-
tava. Tupakointi, mahdollinen ympäristöperäinen kohdunkaulansyövän osatekijä, 
on herättänyt kasvavaa mielenkiintoa 1980-luvulta lähtien. Tarkoitukseni oli täs-
sä työssä määrittää tupakoinnin rooli kohdunkaulansyövässä ja sen esiasteissa sekä 
HPV-infektioissa, ja arvioida tupakoinnin vaikutusta luonnollisen HPV-infektion 
ja toisaalta rokotuksen seurauksena syntyneelle immuunivasteelle.
Väestöpohjainen upotettu tapaus-verrokkitutkimus hyödynsi viittä pohjois-
maista (Islanti, Norja, Ruotsi, Suomi) seerumipankkikohorttia. Tapausten ja ver-
rokkien näytteistä tutkittiin kotiniini (tupakoinnin biomarkkeri) ja HPV, herpes 
simplex virus ja klamydia vasta-aineet. Pienen otoskoon vuoksi ensimmäisen tut-
kimusmateriaalin mahdollisuudet erottaa onko tupakointi kohdunkaulan syövän 
kehittymisen itsenäinen riskitekijä vai selittyykö osuus syöpävaarallisten HPV:n 
jäännössekoitusvaikutuksella (osajulkaisu I) ei ollut mahdollinen. Toiseen tutki-
musmateriaaliin (osajulkaisu I) keräsimme neljä kertaa suuremman, erillisen, ma-
teriaalin, jossa oli 588 tapausta ja 2861 verrokkia. Osoitimme tupakoinnin ole-
van kohdunkaulansyövän itsenäinen riskitekijä. Löysimme erittäin merkitsevän 
2–3-kertaisen kohdunkaulansyöpäriskin (vaarasuhde, OR = 2.1; 95 % luottamus-
väli (CI): 1.4–3.2) ja levyepiteelisyöpäriskin (OR = 2.7; 95% CI: 1.7–4.3) HPV16/18 
vasta-ainepositiivisten aktiivisten tupakoitsijoiden joukossa, joka oli vapaa jään-
nössekoitus-vaikutuksesta. Lisäksi piste-estimaatit olivat sitä suurempia mitä kor-
keampi tutkittavien ikä oli diagnoosihetkellä (so. mitä pitempi altistuminen) ja mi-
tä korkeampi heidän kotiniinitasonsa.
Tekemässämme poikkileikkaustutkimuksessa (osajulkaisu II) vertasimme tu-
pakoitsijoiden ja purutupakan käyttäjien useiden HPV infektioiden ja kohdunkau-
lansyövän esiasteiden (SIL) riskiä kahdessa populaatiossa. Tutkimuksessa oli 2 162 
naista Norsunluurannikolta Länsi-Afrikasta ja 419 naista Suomesta, Pohjoi-Euroo-
pasta, joista oli käytettävissä tiedot kohdunkaulansyövän seulontatutkimuksesta, 
tupakoinnista ja purutupakan käytöstä, kohdunkaulan HPV DNA löydöksistä, kla-
mydia ja HIV vasta-ainetiedot. Molemmissa tutkittavien ryhmissä tupakka-altistus 
(purutupakan käyttäjillä ja tupakoitsijoilla) liittyi kohonneeseen matala-asteisen 
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SIL-muutoksen riskiin sekä nuoremmilla (OR = 5.5, 95% CI: 1.2–26) että vanhem-
milla (OR = 5.5, 95% CI: 2.1–14) tutkittavilla. Löysimme, ei-tilastollisesti merkitse-
västi, kohonneen matala- ja korkea-asteisten SIL-muutosten riskin yli 30-vuotiailla 
tupakka-altistuneilla (purutupakan käyttäjät tai tupakoitsijat) tutkittavilla. Heidän 
useiden HPV-infektioiden riskinsä ei ollut kohonnut.
Kohorttitutkimuksessa (osajulkaisu III) arvioimme tupakoinnin liittymis-
tä kiertäviin HPV vasta-aineisiin 191 HPV-infektioon sairastuneella naisella, joita 
seurattiin aina 10 vuotta kohdunkaulansyövän seulontanäytteillä joista määritettiin 
myös HPV-DNA.Tutkimuksen alku- ja loppuhetkillä otetut näytteet tutkittiin koti-
niini, ja HPV16 ja HPV18 immunoglobuliini (Ig) G ja IgA vasta-aineiden suhteen, 
myös klamydia vasta-aineet määritettiin ELISA-menetelmällä. Nuoret tupakoitse-
vat naiset serokonvertoivat HPV16/18 viruksille tai säilyttivät nämä vasta-aineensa 
10 seurantavuoden ajan vähemmän todennäköisesti kuin tupakoimattomat. Tämä 
viittaa siihen, että nuorilla naisilla, joilla on syöpävaarallisten HPV16/18 virus-
ten aiheuttama infektio, tupakointi huonontaa vasta-aineresponssia korkean ris-
kin HPV-virustyypeille.
Kaksoissokkoutettuun, satunnaistettuun faasi III tutkimukseen osallistui Suo-
messa 4808 16–17-vuotiasta naista, ja he saivat joko HPV16/18 AS04-adjuvantoi-
tua viruksen kaltaisista partikkeleista (VLP) koostuvaa rokotetta tai kontrollina he-
patiitti A rokotetta (HavrixTM) (osajulkaisu IV). Teimme pilottitutkimuksen 216 
tutkittavan joukossa vertaamalla HPV16/18 vasta-aineita tupakoimattomilla ja tu-
pakoitsijoilla 7 kuukautta rokotuksen aloittamisesta (kuukausi kolmannen roko-
tuskerran jälkeen). Alkuhetken ja 7 kuukauden seeruminäytteistä analysoitiin ko-
tiniini ja HPV16 ja HPV18 IgG vasta-aineet. Naisilla, jotka tupakoivat ja jotka eivät 
tupakoineet HPV16 ja HPV18 vasta-aineet olivat samalla tasolla 7 kuukautta ro-
kotuksen jälkeen. Tuloksemme viittaa siihen, että tupakoinnilla ei ole vaikutusta 
HPV rokotuksen seurauksena syntyvään vasta-aineresponssiin.            
Tulostemme mukaan HPV-rokotus ja seulontaohjelmia, ja kohdunkaulansyö-
vän varhaista diagnostiikkaa kehitettäessä myös kansanterveystyö tupakoinnin ja 
purutupakan käytön vähentämiseksi olisi perusteltua, erityisesti nuorilla naisilla.
Avainsanat: ihmisen papilloomavirus, seroepidemiologia, tupakointi, purutupakan 
käyttö, immuuniresponssi, hedelmällisessä iässä olevat naiset, HPV rokote, 
kohdunkaulansyövän ehkäisy
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1 Introduction
Cervical cancer (CC) is the second most common cancer among women 
worldwide. The majority (83%) of cases occur in the developing world, where in 
most countries, CC is the leading cause of cancer mortality among females (World 
Health Organization (WHO) 2003, Ferlay et al. 2004). Cervical infection with 
oncogenic human papillomaviruses (HPVs) is the main cause of CC (Walboomers 
et al. 1999). Of the numerous oncogenic high-risk (hr) HPV types, 70% of CC is 
attributed to HPV16 and HPV18 (Bosch et al. 2002, Lehtinen et al. 2001). However, 
infection with HPV cannot be a sufficient cause of CC because of the high numbers 
of HPV-infected women who do not develop cancer (Walboomers et al. 1999). It is 
likely that environmental and host-related cofactors act in conjunction with HPV 
to promote malignant progression of squamous intraepithelial lesions (SIL), which 
is the clinical manifestation of hrHPV infection.
Tobacco exposure, an environmental factor in human cancers, is of interest in 
cervical carcinogenesis because of: 1) the correlation of increased incidence lung 
cancer and CC (Korhonen et al. 1999), 2) the consistent association of smoking 
with cervical intraepithelial neoplasia (CIN) grade 3 and CC (Plummer et al. 
2003), 3) the comparable strength of the association between tobacco smoking 
and chewing and CC (Rajkumar et al. 2003) 4) biologic plausibility, including 
the observation of nicotine-derived carcinogens in cervical mucus after smoking 
(Holly et al. 1993) and 5) the potential for intervention through anti-smoking 
campaigns (Nandakumar et al. 2005).
For development, evaluation and effective implementation of prevention 
strategies and therapeutic agents against hrHPV infection and CC, a better 
understanding of the impact of tobacco exposure on hrHPV infection, associated 
natural and vaccine induced immune responses, and cervical carcinogenesis is 
required.
18 Research 20
THL 2009
Epidemiological Study of Tobacco Use and 
Human Papillomavirus
Aline Simen-Kapeu
2 Review of the litterature
2.1  Tobacco use
2.1.1  History and epidemiology 
The history of smoking starts among the Native Americans who used it for 
ceremonial purposes 5000 years BC. Christopher Columbus first brought tobacco 
to Europe from the West Indies in 1492. From the beginning it was used for medical 
purposes and in history it is mentioned when the Queen of France, Catherine of 
Medici, was cured from stomach pains by tobacco. She got the tobacco from Jean 
Nicot and named it “Nicotiana”. Soldiers during the great European wars spread 
the use of tobacco, mostly used as snuff or smoked in pipes. It was not until the 
Crimean War, in the middle of 19th century, that cigarettes became more common.
When the first cigarette machine was constructed in 1870, cigarette smoking 
flourished. This was also the start for the big tobacco companies (Goodman 1995). 
Cigarette smoking was from the beginning a masculine habit and spread among 
soldiers during World War I and II. Women began to take up smoking during 
and after World War II, thus putting children in closer contact to environment 
tobacco smoke (ETS). The era of the well-educated and career-oriented women 
began; smoking became a sign of independence and was seen as part of women’s 
liberation. Cigarette smoking then spread to other groups in society. While the 
well-educated women are now dropping the habits because of increased health 
awareness, it has now become most prevalent among underprivileged women with 
low education attainment (Torell 2002). 
Worldwide, about 50 % of males and 10 % of females are smoking, but there 
are great variations among nations. In Finland, 26 % of 15 to 64-year-old males 
and 18 % of females smoked daily in 2005 (Helakorpi et al., 2005). Smoking 
prevalence among 13 to15-year-olds ranges from 1 % to 40 % in different countries 
(Global Youth Tobacco Survey (GYTS) Collaboration Group 2002). During the 
last decade smoking prevalence has decreased in the Western world but increased 
in the developing countries (Shafey et al. 2003). In the developing countries too, 
men started smoking first and women followed soon thereafter. Globally, tobacco 
consumption as well as production is growing and women in Asia and Africa are 
now the main target group for the tobacco companies (Mackay and Eriksen 2002). 
Though smoking prevalence in the Western world is decreasing, smoking has 
kept an aura of tough and smart glamour, and around 100, 000 new young smokers 
are recruited daily (Mackay and Eriksen 2002). In total, about 1/3 of the adult 
population smokes and WHO has calculated that 1000 cigarettes are manufactured 
per year per person, including women and children (Mackay and Eriksen 2002). A 
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nearly two-fold difference in smoking rates is seen in men across different WHO 
regions, with the lowest level in the Eastern Mediterranean Region (34.2%) and the 
highest in the Western Pacific Region (62.3%). Based on these weighted prevalence 
estimates, there are over 1.2 billion smokers across the six WHO regions, women 
being in the minority in the developing countries (Table 2.1).
The prevalence of smokeless tobacco use is high among women. In Mumbai, 
59% of women used smokeless tobacco (Gupta 1996). The prevalence was similar 
to that of other South-Asian female populations. Around 49% of UK-Bangladeshi 
females, 35.5% of Nigeran females and 59% of rural Malesian females use smokeless 
tobacco (Thomas et al. 2004, Gan 1995, Croucher et al. 2002). Women appear to 
have a higher prevalence of the chewing habit in many countries of the South due 
to the belief that tobacco has many magical and medicinal properties; keeping 
the mouth clean, getting rid of bad smell, curing toothache, controlling morning 
sickness, and minimizing labour pains (Muwonge et al. 2008).
Tobacco use prevalence can be decreased by a variety of tobacco prevention 
and control efforts. Reporting on the adverse health effects from smoking the 
anti-smoking debate was accelerated in the 1980’s when it was shown that passive 
smoking was also a health hazard. During the 1990’s numerous conventions, 
national as well as international, addressed the smoking issue. Educational, clinical, 
regulatory, economic, and comprehensive approaches are widely used and studied. 
WHO and European Union, have made up rules and recommendations for how the 
TABLE 2.1. Prevalence of tobacco use and number of smokers by WHO region and levels of development 
in 2000
Prevalence
(% of the population 
≥15 years of age)
No. of tobacco users
(thousand)
Men Women Total Men Women Total
Who region
African Region
Region of the Americas
Eastern Mediterranean 
Region
European Region
South East Asia Region
Western Pacific Region
Level of development
Developed
Developing
Transitional
World
29.4
32.0
35.3
44.9
48.1
61.2
33.9
49.8
54.1
47.5
7.4
20.9
6.1
18.7
5.3
5.7
21.2
7.2
13.9
10.3
18.4
26.3
21.0
31.2
27.3
33.8
27.4
28.9
32.7
28.9
51,967
94,035
52,543
150,628
251,699
390,632
114,783
809,725
82,837
11,005,927
13,420
64,072
8,670
68,545
26,484
35,784
75,891
114,718
24,153
217,755
65,387
158,107
61,213
219,173
278,183
426,146
190,673
924,443
106,989
1,223,682
From Guindon and Boisclair 2003.
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“pandemic of smoking” can be defeated. Tobacco control is highly cost-effective 
(World Bank 1999). Many countries have passed laws on smoke free areas, rules for 
cigarette commerce and public health interventions to control tobacco use. 
As an example in Finland, the Tobacco Control Act was passed as early as in 
1976 (Puska et al. 1997). It prohibited smoking in most public places, restricted 
tobacco advertising, and set a 16-year age limit for tobacco purchases. Further 
amendements to the Act were made in 1995, when, for example, the age limit for 
tobacco purchases was raised to 18 years, and in 2000, when ETS was included in 
the national list of carcinogenic substances. Among Finnish adult males, smoking 
prevalence is nowadays one of the lowest in Europe (Shafey et al. 2003). In general, 
the smoking trends suggest that the impact of tobacco policy is decreasing smoking 
initiation in youth (Helakorpi et al. 2004); for example the legislation appears 
to have decreased purchases from commercial sources to minors (Rimpelä and 
Rainio 2004). 
2.1.2  Global burden of tobacco use for public health
Tobacco is packed with harmful and addictive substances. Scientific evidence has 
shown conclusively that all forms of tobacco cause health problems throughout 
life, frequently resulting in death or disability. Smokers have markedly increased 
risks of multiple cancers, particularly lung cancer, and are at far greater risk of 
heart disease, stroke, emphysema and many other chronic diseases. The use of 
smokeless tobacco causes cancer in humans (International Agency for Research on 
Cancer (IARC) 2004). Smokeless tobacco contains carcinogens, which contribute 
to cancers of the oral cavity and the risk of other cancers. Smokeless tobacco use 
also causes a number of noncancerous oral conditions and can lead to nicotine 
addiction similar to that caused by cigarette smoking.
Women who smoke suffer additional health risks. Smoking in pregnancy is 
dangerous to the mothers as well as to the foetus, especially in countries where 
health facilities are inadequate. Smoking is not only harmful during pregnancy, 
but has long-term effects on the offspring. This is often compounded by exposure 
to passive smoking by the mother, father or other adult members (Fenercioglu et 
al. 2009).
Of today’s global population, 650 million will eventually be killed by tobacco. 
Approximately half of smokers are killed by their habit – a quarter while still in 
middle age (35-69 years) (Peto et al. 1996). On average, smokers die ten years 
younger than non-smokers. Tobacco kills more than Acquired Immuno Deficiency 
Syndrome (AIDS), legal drugs, illegal drugs, road accident, murder and suicide 
combined (Doll et al. 2004). Tobacco already kills more men in developing countries 
than industrialized countries, and it is likely that death among women will soon be 
the same. Annual deaths due to tobacco in industrialized countries were 1.3 million 
in 1995 and reached 2.1 million in 2001 and will increase further to 3 million by 
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2025–30, whereas in developing countries this was 0.2 million in 1975, 2.1 million 
in 2001, and 7 million by 2025–30, which is a very rapid increase (WHO 2008). 
While 0.1 billion people died from tobacco use in the 20th century, ten times as 
many will die in the 21st century. The main diseases by which smoking kills people 
are substantially different in America (where vascular diseases and lung cancer 
predominate) (Peto et al. 2004), than in China (where obstructive pulmonary 
disease predominates, causing even more tobacco deaths than lung cancer) (Liu et 
al. 1998, Niu et al. 1998), or in India (where half of the world tuberculosis deaths 
take place, and the ability of smoking to increase the risk of dying from tuberculosis 
is of particular importance) (Gajalashmi et al. 2003). Around the world, it is 
estimated that there are currently 30 million individuals who start to smoke every 
year. With current smoking patterns, worldwide mortality from tobacco is likely to 
rise from 2–3 million deaths a year in 2001 to about 10 million a year around 2030 
(WHO 2008). A survey conducted in 1990 in 44 industrialized countries showed 
that smoking caused an average of 24% of all male deaths – but 35% of these deaths 
occur in middle age (35–69 years). This proportion was about 12% in Chinese 
middle-aged men but is expected to rise to about 33% by 2030. Currently, smoking 
causes 7% of all female deaths overall.   
2.1.3  Smoking forms of tobacco use 
There is a variety of smoking tobacco products on the world market (Table 2.2).
Cigarette is any roll of tobacco wrapped in paper or other non-tobacco material; 
filter-tipped or untipped; approximately 8 mm in diameter, 70–120 mm in length.
A cigar is any roll of tobacco wrapped in leaf tobacco or in any other substance 
containing tobacco. There are four main types of cigars: little cigars, small cigars 
“cigarillos”, regular cigars and premium cigars. Some little cigars are filter tipped 
and are shaped like cigarettes. Little cigars contain air-cured and fermented 
tobacco and are wrapped either in reconstituted tobacco or in a cigarette paper that 
contains tobacco and/or tobacco extract. Cigarillos are small, narrow cigars with 
no cigarette paper or acetate filter. Regular cigars are up to 17 mm in diameter, 110-
150 mm in length. Premium cigars (hand-made from natural, long filter tobacco) 
vary in size, ranging from 12 to 23 mm in diameter and 127 to 214 mm in length 
(Stratton et al. 2001). The chemical composition of the tobacco leaf is determined 
by plants genetics, cultivation practices, weather conditions and curing methods 
(Tso 1991). Cigarettes and cigars use blended tobaccos and the type of tobacco 
used in these products has a decisive influence on the physicochemical nature of 
the smoke they produce.
Bidis are the most popular form of smoking of tobacco in India. They are 
also becoming increasingly popular among teenagers in the USA (Malson and 
Pickworth 2002). A bidi is made by rolling a rectangular piece of a dried temburni 
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leaf around approximately 0.2–0.3 g of sun-dried, oriental tobacco and securing 
the roll with a thread. These cigarettes are perceived by some as a better-testing, 
cheaper, safer or more natural alternative to conventional cigarettes (Malson et al. 
2001, Stanfill et al. 2003).
Chuttas are coarsely prepared cheroots with 2–9 cm long, prepared by rolling 
local tobacco inside a sun-dried tobacco leaf. They are usually the products of 
cottage or small-scale industries. Nearly 9% of the tobacco produced in India is 
used for making chuttas. It is estimated that about 3000 million chuttas are made 
annually in India. The term “reverse smoking” is used to describe smoking while 
keeping the glowing end of tobacco product inside the mouth. Reverse chutta 
smoking is practised extensively by women in the rural areas of Visakhapatnam 
and the Srikakulam district of Andhra Pradesh (Van der Eb et al. 1993). 
A cheroot is a roll made from tobacco leaves. Cheroots were commonly smoked 
by both Indian men and women in South India. Dhumti is a kind of conical cigar 
made by rolling tobacco leaf in the leaf of another plant. Unlike bidis and chuttas, 
dhumtis are not available from vendors but are prepared by the smokers themselves 
(Bhonsle et al. 1976). 
Kreteks are types of small cigarettes that contain tobacco (approximately 
60%), ground clove buds (40%) and cocoa, which gives a characteristic flavour 
and “honey” taste to the smoke (Stratton et al. 2001). Kreteks are indigenous to 
Indonesia, but are also available in the USA. 
Pipe smoking is one of the oldest from of tobacco use. The different kinds of pipes 
used for smoking range from the small – stemmed European types made of wood 
to long-stemmed pipes made from metal or other material.
A hookah is an Indian white pipe in which the tobacco smoke passes through 
water before inhalation. It used to be more common among women, the reason 
being that it was inconvenient for men to carry a hookah, whereas women remain 
at home for most of the time.
Hooklis are clay pipes commonly used in western India. Once the pipe is lit, 
it is smoked intermittently. On average, 15 g of tobacco is smoked daily. Hookli 
smoking was common among men in the Bhavnagar district of Gujarat (Mehta et 
al. 1969).
A chillum is a straight conical pipe made of clay, 10–14 centimetres long, held 
vertically. It is exclusive and common among men and is confined to the northern 
states of India, predominantly rural areas (Wahi 1968). 
   
2.1.4  Smokeless forms of tobacco use
Smokeless tobacco products have existed for thousands of years among populations 
in South America and Southeast Asia. Over time, these products have gained 
popularity throughout the world. Smokeless tobacco is consumed without burning 
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the product, and can be used orally or nasally. There are different types of smokeless 
tobacco products (STP) in use around the world. Oral smokeless tobacco products 
are placed in the mouth, cheek or lip and sucked (dipped) or chewed. Tobacco 
pastes or powders are used in a similar manner and placed on the gums or teeth. 
Fine tobacco powder mixtures are usually inhaled and absorbed in the nasal 
passages.
Smokeless tobacco comes in two main forms: chewing tobacco (loose leaf, 
in pouches of tobacco leaves, “plug” or “twist” form) and snuff (finely ground or 
cut tobacco leaves that can be dry or moist, loose or portions packed in sachets, 
and administered to the mouth, or the dry products to the nose or mouth). When 
administered orally, the tobacco can also be mixed with other psychoactive 
ingredients. 
A list of the wide range of oral and nasal tobacco products used is presented 
below (Table 2.2). 
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TABLE 2.2 List of smokeless tobacco products by continent
Common name Constituents How used
EUROPE
Moist snuff, Snus Tobacco; water; sodium 
carbonate; sodium chloride; 
moisturizer; flavouring; nicotine
A pinch (called a dip) is usually placed in the upper 
gingivolabial sulcus. The average user keeps snus in 
their oral cavity for 11 to 14 hours per day.
Dry snuff Tobacco Inhaled up the nostrill
Nicotine gum
(non-
pharmaceutical)
Tobacco Gum to be chewed
Gutkha Tobacco Chewed or smoked in pipe
Chewing 
tobacco
Tobacco Chewed or smoked in pipe
NORTH 
AMERICA
Dry snuff Tobacco + aromatic oils, spices Inhaled up the nostril
Loose leaf chew Leaf tobacco; sweetener and/or 
liquorice
A piece of leaf is tucked between the gum and jaw, 
typically toward the back of the mouth. It is either 
chewed or held in place. Saliva spit or swallowed.
Moist plug Enriched tobacco leaves; fine 
tobacco; sweetener and/or 
liquorice
Chewed or held between the cheek and lower lip. 
Saliva may be spit or swallowed.
Moist snuff Tobacco A pinch “dip” or held between the cheek/gum. Saliva 
may be swallowed.
Plug chew Enriched tobacco leaves; fine 
tobacco; sweetener and/or 
liquorice
Chewed or held between the cheek and lower lip.1 
Saliva may be spit or swallowed.
Twist roll (chew) Tobacco; tobacco leaf Extract Chewed or held between the cheek and lower lip. 
Saliva may be spit or swallowed.
Iq’mik Tobacco, punk ash Users pinch off a small piece and chew the iq’mik. 
Often, the user may premasticate the iq’mik and place 
it in a small box for later use by others, including 
children and sometimes teething babies.
SOUTH 
AMERICA
Chimo Tobacco resin; alkaline ash; 
Paullinia yoco; banana peel; 
sugar;
avocado seed
A very small amount of the paste is placed under the 
tongue and absorbed there. Saliva is traditionally spat 
out. Chimo is popular as a replacement for cigarettes 
and provides a similar bolus of nicotine.
Dry snuff, Rapé Dry tobacco powder with 
peppery smell
Sniffed through nostrils
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Common name Constituents How used
INDIA 
SUBCONTINENT
Gul Tobacco powder, molasses, other 
ingredients
Often used for clearing teeth
Gutkha Betel nut, catechu, tobacco, 
lime, saffron, flavouring, 
saccharine, mint
Held in the mouth and chewed. Saliva is generally spit 
out, but sometimes swallowed.
Khaini tobacco; slaked lime paste; areca 
nut
Paste is placed in the mouth and chewed
Mawa Tobacco; slaked lime; areca nut Placed in the mouth and chewed fo 10 to 20 minutes
Tuibur, hidakphu Tobacco water Sipped and held in mouth 5–10 min and then spat out
Mishri (masheri) Tobacco Applied to the teeth and gums, often for the purpose 
of cleaning the teeth. Users then tend to hold it in 
their mouths (due to the nicotine addiction).
Nass (naswar, 
niswar)
Nass: tobacco, ash; cotton or 
sesame oil; water; sometimes 
gum. Naswar or niswar: tobacco, 
slaked lime; indigo; cardamom; 
oil; menthol; water
Held in the mouth for 10 to 15 minutes. Naswar is 
sometimes chewed slowly
Pan masala Tobacco; areca nuts, slaked lime, 
betel leaf. 
A quid is placed in the mouth (usually between the 
gum and cheek) and gently sucked and chewed. Pan 
masala is sometimes served in restaurants after the 
meal.
Zarda Processed tobacco Along with betel quid
Creamy snuff Tobacco, clove oil, glycerine, 
menthol, spearmint, camphor
Often used to clean teeth. The manufacturer 
recommends letting the paste linger in mouth
Red tooth 
powder
Tobacco
MIDDLE EAST
Shammah Tobacco; ash; slaked lime
AFRICA
Toombak Tobacco; sodium bicarbonate Product is rolled into a ball of about 10g called a saffa. 
The saffa is held between the gum and the lip or 
cheeks, or on the floor of the mouth. It is sucked slowly 
for 10 to 15 minutes. Male users periodically spit, while 
female users typically swallow the saliva generated. 
Snuff Tobacco Sniffed through nostrils, portion bags introduced
From the European Scientific Committee on Emerging and Newly Identified Health Risks, 2007.
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2.1.5  Assessment of tobacco exposure 
The selection of a strategy to measure smoking exposure is affected by factors such 
as: (a) required accuracy of the smoking estimate, (b) need for immediate feedback 
to the smoker, (c) accurate disclosure by the target population, (d) concurrent use 
of nicotine replacement therapy, (e) need to distinguish between reduction and 
abstinence, (f) need for validating smoking status, and (g) availability of resources. 
The various approaches differ in accuracy, validity, objectivity, ease of measurement 
approach, acceptability and cost. Research evidence on the measurement strategy 
should guide the decision to use questionnaire data, a biomarker or both.
2.1.5.1  Self-reports
Self-administered questionnaires are a cheap method of assessing smoking status; 
they are easy to use with great feasibility (fit within setting) and accomplished 
by written or verbal communication. In this method, the participant responds 
to questions, either verbally or in writing, regarding smoking abstinence or 
cigarette consumption (number of cigarettes smoked, frequency, and duration). 
Questionnaires are noninvasive for the test subjects and the confidentiality of 
information reduces the refusal rate among participants. Self-reported information 
can be used to measure behavioural change, to evaluate the exposure risk or to study 
pathways to smoking cessation (Bauman et al. 1989, Wills and Cleary 1997). The 
validity of questionnaire data has been studied (Vartiainen et al. 2002). In special 
groups (adolescents, pregnant women), self-reported smoking is more likely to be 
under-reported (Owen et al. 2001, Britton et al. 2004, Burstyn et al. 2009).
2.1.5.2  Biochemical methods
The term biomarker means a measurement that reflects an interaction between 
a biological system and a chemical, physical, or biological environmental agent 
(Haufroid and Lison 1998). Biological quantification of tobacco use is based on 
some aspect of the composition of inhaled tobacco smoke. Tobacco smoke is 
composed of gaseous and particle components. The gaseous component is made 
up of room air, carbon monoxide, nicotine and volatilized hydrocarbons such 
as hydrogen cyanide. The primary particle component of tobacco smoke is tar, 
which carries nicotine. Substances such as nicotine, cotinine, thiocyanate, carbon 
monoxide and some minor alkaloids of nicotine have been identified and tested 
as biomarkers of both active cigarette smoking and second hand smoke exposure 
(SHS) (Woodward et al. 1991). 
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Nicotine
The major and most pharmacologically active alkaloid of tobacco is nicotine (Jacob 
et al. 1999). The amount of nicotine uptake is dependent on a smoker’s inhalation 
behaviours (e.g. deep or long inhalation of smoke) and metabolism of nicotine 
(Benowitz 1999). Most nicotine is metabolized into cotinine and eventually 
excreted (see cotinine below). Nicotine may be extracted and measured from 
blood, saliva, and urine (Benowitz 1996). More recently, it has been measured 
from samples of hair and toenails (Al-Delaimy et al. 2002). Nicotine as a biomarker 
agent, however, is of limited use (Velicer et al. 1992). Any assay using nicotine must 
be very sensitive because of the small amount of nicotine present in body fluids. 
Furthermore, because of its short half-life (2 hrs) and individual variation in its 
rate of metabolism (Benowitz et al. 1996, Idle 1990), nicotine levels can be only 
approximated, and may give a biased estimate of tobacco use/exposure.
Thiocyanate
Tobacco smoke contains high concentrations of hydrogen cyanide gas, which 
is primarily metabolized into thiocyanate (SCN). Like cotinine, SCN can be 
measured in blood, urine and saliva (Velicer et al. 1992). The following issues affect 
the usefulness of SCN as a biomarker. Despite its long half-life (10–14 days), the 
sensitivity and specificity of the assay method are low. SCN levels are influenced 
by industrial exposure and dietary intake (almonds, bamboo shoots, sugar cane, 
cauliflower, broccoli, beer and ale (Benowitz 1999, Woodward et al. 1991). Because 
of these limitations, determination of SCN has not gained wider use (Scherer and 
Richter 1997, Velicer et al. 1992).
Carbon monoxide (CO) 
Cigarette smoke contains a high concentration of CO in gaseous form. Regular 
cigarette smoking may produce carboxyhemoglobin (COHb) levels ranging from 
5% (1 pack per day) to 9% (2–3 packs per day), whereas heavy cigar smoking can 
produce COHb levels up to 20%. CO has a half-life of 4–5 hrs in adults and can be 
measured in both exhaled alveolar air and blood (Stewart 1975). Although CO can be 
measured by analysis of hemoglobin for COHb using a carbon monoxideoximeter 
instrument, this approach is not favoured because the procedure to collect the 
specimen (blood) is invasive. Instead, a much simpler and direct measurement of 
CO can be accomplished using exhaled air and a simple handheld breath analyzer. 
This method does not require the samples, such as those of blood, saliva, or urine, 
to be collected and stored, and only minimal training is needed in using the device. 
The immediately available measurement of CO level, which is shared with the 
smoker, can depict the detrimental effects of smoking. This may affect the smoker’s 
subsequent smoking behavior (Secker-Walker et al. 1997). Thus, CO measurement 
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has been used as part of anti-smoking campaigns. Researchers have demonstrated 
high correlations among CO, self-reported smoking and urinary cotinine (Secker-
Walker et al. 1997). Exhaled CO has been successfully used to corroborate self-
report data, with concordance approaching 100% (Becona and Vazquez 1998). 
Environmental sources of CO can result in CO levels indistinguishable from 
those produced by direct cigarette use, thereby confounding the measurement 
(Velicer et al. 1992, Becona and Vazquez 1998). Another disadvantage of CO 
measurement is the relatively short half-life of CO (4–5 hrs). In general population, 
false-negative rates of CO measurements have been found to range from 2% to 
16% (Velicer et al. 1992). In addition, the sensitivity decreases with infrequent 
and irregular smoking patterns, causing those who are light or atypical smokers to 
appear indistinguishable from non-smokers (Jarvis et al. 1987, Lando et al. 1991).
Cotinine
Cotinine is a useful and popular biomarker of tobacco use. Most nicotine entering 
the body (70%–80%) is metabolized into cotinine. Cotinine is present in the blood 
serum, saliva, urine, amniotic fluid, cervical mucus and hair of both smokers and 
non-smokers exposed to tobacco smoke. It has been cited as the most useful marker 
for distinguishing tobacco users from non-users, for estimating the nicotine intake 
of tobacco users, and for specifying the exposure of nonsmokers to second hand 
smoke (Benowitz and Jacob 1994). Cotinine has an extended biological half-life 
(15–40 hrs). Its level in the body is directly related to the quantity of nicotine 
absorbed during the last few days (Wagenknecht et al. 1990). The presence of 
cotinine indicates exposure to nicotine, either from environmental exposure or 
direct consumption. 
An advantage of cotinine as a biomarker is its high sensitivity. It can distinguish 
very low levels, such as from SHS in non-smokers, from levels associated with 
cigarette smoking. Small amounts of cotinine in the body can result from ingestion 
of foods rich in nicotine (such as cauliflower, eggplant, potatoes, tomatoes and black 
tea), but these levels are considered insignificant (Benowitz 1996). Measurement 
techniques have been developed. Cotinine can be quantified in blood, serum, saliva 
and urine. Various techniques are used for quantitative analysis including: (a) 
radio immunoassay, (b) high-performance liquid chromatography, (c) gas–liquid 
chromatography and (d) gas chromatography combined with mass spectrometry 
(SNRT Committee for Biochemical validation 2003, James et al. 1998). Woodward 
and colleagues (1991) compared cotinine levels with those from exhaled CO, self-
reported tobacco exposure and thiocyanate. The results showed a high correlation 
among all the markers for the smoking group, but a lower correlation among the 
nonsmokers exposed to second hand smoke. The investigators concluded that 
cotinine is the most accurate discriminator between smokers and non-smokers 
(Woodward et al. 1991). In other studies, serum cotinine was demonstrated to be 
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a better measure of cigarette smoking than was questionnaire (Perez-Murray et al. 
1993, Stable et al. 1995, Britton et al. 2004, Burstyn et al. 2009).
Exhaled carbon monoxide and cotinine (detected in blood, urine or saliva) 
are sufficiently sensitive, specific and feasible for general use, and are therefore 
frequently used as biomarkers of cigarette smoking.
New biomarkers and strategies to detect tobacco exposure
A number of new biomarkers are under development. One new strategy is to use 
hair specimens for analysis of cotinine in order to assess individuals’ smoking 
history. Although there are limitations, such as confounders caused by hair color, 
hair dyes and other chemical treatments, a statistically significant correlation 
between hair cotinine and nicotine intake has been found (Eliopoulos et al. 1996). 
This strategy is promising because of the noninvasive nature of the test, the lack 
of stringent specimen storage requirements and the ability to detect a history of 
tobacco usage in patients who temporarily abstain from smoking prior to testing 
(Eliopoulos et al. 1996). 
Biochemical validation is often considered to be a “gold standard” (= 
considered more accurate than self-reported habit) in validation studies. When 
used in combination with self-report, biomarkers provide information about the 
concurrent validity of self-report, and have been noted to increase the accuracy 
of self-reporting (Kathleen and Muñoz 2004, Wagenknecht et al. 1992, Clark et al. 
1996, Becona and Vazquez 1998).
2.2  Cancer of the uterine cervix
2.2.1  Epidemiology
Cancer of the uterine cervix is the seventh most common cancer overall and the 
second most frequent cancer in women worldwide (Ferlay et al. 2004; Denny 
2008). It is a major cause of morbidity, mortality and premature death among 
middle-aged women in developing countries, who account for 80% of the annual 
estimated 493,000 new cases and 274,000 deaths worldwide. In these low resourced 
countries, cervical cancer accounts for 15% of female new cancer cases, with an 
absolute cumulative risk of 1.5% before the age of 65 years. In developed countries, 
these proportions are smaller with only 3.6% of new cancers and a cumulative risk 
of 0.8%. If effective preventive interventions are not implemented, over 1 million 
women will suffer from cervical cancer annually by the year 2030 (Denny 2008), 
leading to a far greater in risk and disease burden in developing countries compared 
to developed countries, and increasing the social inequalities.
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The highest incidence rates are observed in the developing countries in sub-
Saharan Africa, Melanesia, Latin America and the Carribean, South-Central and 
Southeast Asia, with age-standardized (world population) incidence rates ranging 
from 18.7 to 42.7 per 100,000 (Maucort-Boulch et al. 2008). In more developed 
regions, these rates are generally lower than 14.5 per 100,000 (Parkin et al. 2005; 
Parkin 2008). These lower incidence rates have, however, materialized after the 
introduction of screening programmes in the developed countries in the 1960s. 
Earlier, the incidence in the developed countries was similar to that of developing 
countries today in most of Europe, North America and Japan (Gustafsson et al. 
1997). Cervical cancer incidences were estimated to be 38.0 per 100,000 in the 
Second National Cancer Survey of the United States (Dorn et al. 1959), 37.8 per 
100,000 in Hamburg, Germany in 1960–62, 28.3 per 100,000 in Denmark in 1953–
57 and 22.1 per 100,000 in Miyagi, Japan in 1959–60 (Doll et al. 1966) The lowest 
rate of cervical cancer, 0.4 per 100,000, has been reported in Ardabil, northwest 
Iran (Sadjadi et al. 2003). Very low rates have also been observed in Israel (2.0 per 
100,000), China (6.8 per 100,000), Western Asia (5.8 per 100,000) and Finland (4.0 
per 100,000) (Parkin et al. 2005).
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Mortality from cervical cancer is considerably lower than the incidence in 
both developing and developed countries but the mortality to incidence ratio is 
higher for the former (57%) than the latter (47%) (Ferlay et al. 2004). Survival rates 
vary between regions with good prognosis in regions with low incidence (survival 
obtained from case fatality ratio was 70% for USA, 66% for Western Europe and 
65% for Japan in 2002) and fairly good prognosis even in some developing regions 
(55% in South America and 58% in Thailand) where many cases present at a 
relatively advanced stage (Parkin et al., 2005). However, poor prognosis is seen in 
sub-Saharan Africa (21%) (Parkin et al. 2008). 
2.2.2  Natural history
Invasive CC is usually preceded by a long phase of pre-invasive, occult disease. 
This pre-invasive disease is microscopically assessed and characterized as a 
spectrum of progressive lesion with severity ranging from cellular atypia to various 
grades of dysplasia or cervical intraepithelial neoplasia (CIN) before progression 
to invasive carcinoma. Using different terminology systems (Table 2.3), cervical 
cancer precursor lesions are commonly classified into mild dysplasia or CIN I, 
moderate dysplasia or CIN II, and severe dysplasia or CIN III. However, the newer 
terminology of the precursor lesions classifies them as squamous intraepithelial 
lesions (SILs), which are graded as low (combines condylomatous (HPV) changes 
and CIN I) and high (encompasses more advanced CIN such as CIN II and III) 
(Sellors et al. 2003). 
Infection of the cervical epithelium with specific hrHPV types plays a 
fundamental role in the development of cervical cancer through its precursor lesions 
(Zur Hausen 1999, Whiteside 2008). HPV DNA has been detected in virtually 
all cervical cancer specimens (Walboomers et al. 1999, Subramanya and Grivas 
2008) with HPV16 having the dominating role followed to a lesser degree by HPV 
types 18, 31, 33 and 45 (IARC 2006). Most cervical abnormalities caused by HPV 
TABLE 2.3 Terminology of cervical precancerous abnormalities
Dysplasia terminology Cervical Intraepithelial 
Neoplasia (CIN) system
Bethesda system
Unspecified cellular 
changes
Cellular atypia Atypical Squamous Cells of 
undetermined significance 
(ASCUS)
Mild dysplasia CIN I Low-grade squamous 
intraepithelial lesions (LSIL)
Moderate dysplasia
Severe dysplasia/
Carcinoma in situ (CIS)
CIN II
CIN III (includes CIS)
High-grade squamous 
intraepithelial lesions 
(HSIL)
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infections do not progress to high-grade SILs (HSIL) or cervical cancer, but regress 
spontaneously. The long timeframe between initial infection and overt diseases 
indicates that other exogenous and endogenous cofactors, such as reproductive 
factors, other sexually transmitted diseases, smoking, nutritional deficiencies and 
genetic susceptibility, acting in conjunction with the hrHPVs probably participate 
in disease progression (Sellors et al. 2003, Stewart et al. 2003, Woodman et al. 2007, 
Castro 2008). Spontaneous regression of CIN suggests that a lot of women may not 
be exposed to these cofactors.
Figure 2.1 Natural history of HPV from Woodman et al. 2007 (Nature Reviews, Cancer)
Studies addressing the natural history of CIN, with particular emphasis on 
disease regression, persistence and progression, have demonstrated that most LSIL 
regress to normal within relatively short time-periods or do not progress to severe 
lesions or invasive disease (Mitchell et al. 1994, Melnikov et al. 1998, Holowaty 
et al. 1999, Schlecht et al. 2003, Bosch et al. 2008, Wheeler 2008). On the other 
hand, HSIL has a greater likelihood of progressing to invasive cancer, though a 
proportion of such lesions also regress or persist (Stanley 2007, Bosch et al. 2008, 
Wheeler 2008). The mean interval for progression from CIN to ICC ranges between 
10 and 20 years.   
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2.2.3  Risk factors
2.2.3.1 Human Papillomavirus
Structure and classification
Human papillomaviruses belong to the Papillomaviridae family. They are small, 
non-developed, double-stranted DNA viruses with icosahedral symmetry. The 
virion has a diameter of 55–60 nm and the viral genome is approximately 7900 
base pairs long (Chen et al. 1982). The protein coat is composed of 72 capsomers 
consisting of two structural proteins: one major protein (L1) representing 80% of 
the total capsid. L2 is the minor protein.
To date, at least 100 HPV types have been classified (de Villiers et al. 2004, 
IARC 2006). They are classified as genotypes and each type has a given number. The 
genotypes are based on the sequence homology of the L1 open reading frame (ORF) 
because this region is well conserved among all members of the papillomavirus 
family. If the DNA sequence of a new HPV type differs by more than 10% from the 
closest known papillomavirus type it will be recognized as a new type. A subtype 
is defined when there is 2–10% difference in the sequence homology. Less than 2% 
defines a variant (de Villiers et al. 2004).
HPVs are grouped according to the type of epithelia they infect. The majority 
of HPVs infect cutaneous epithelia or skin. Approximately 40 types infect mucosal 
epithelia and are called genital HPVs. These types are divided into high-risk types, 
including cell transformation and low-risk types, causing benign warts, and further 
divided by sequence homology into A9 (HPV16, 31, 33, 35, 52, 58, 67), A7 (HPV18, 
39, 45, 59, 68, 70) (Centers for Disease Control 2008). It has been suggested that 
at least 14 types are high-risk types (Bosch et al. 1995, IARC 1996, IARC 2006). 
Main difference between the two major categories is represented by the exclusive 
capacity of the high-risk HPVs to integrate the host cell’s chromosome (Ferenczy 
and Franco 2001).
Genomic organisation
The genome of HPV contains approximately eight ORFs, which are transcribed from 
a single DNA strand (Fehrmann and Laimins, 2003). In the upstream regulatory 
region (URR) which is a non-coding region, sequences for viral replication are 
found. The gene products can be divided into two classes: early (E) and late (L) 
proteins (Howley 2006) (Figure 2.2). The early genes are primarily responsible for 
viral DNA replication, transcription and transformation and the late genes express 
viral structural proteins that are responsible for maturation and assembly of the 
virus particle.
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FIGURE 2.2 HPV 16 genome organisation 
E1 is the largest ORF in the papillomavirus genome. It is the only papillomavirus 
protein with defined enzymatic activity (helicase and ATPase activity), which helps 
viral DNA replication to occur in an efficient manner (Wilson et al. 2002). E1 forms 
heterodimers with E2, which leads to the initiation of viral replication at the viral 
origin (Sverdrup and Khan 1995, Horner and DiMaio 2007). 
The E2 protein has an important role in the life cycle of papillomavirus because 
it regulates viral transcription and replication (Lambert 1991). E2 has been shown 
to induce S-phase arrest, which allows sustained synthesis of viral DNA replication, 
something that is essential for completion of the viral life cycle (Hamid et al. 2009). 
The ORF of E4 is found within the ORF of E2 but has a shorter reading frame. 
The protein is detected in productively infected cells. The E4 protein is translated 
from a spliced E1^E4 transcript to form a spliced E1^E4 fusion protein. The pattern 
of E4 distribution suggests that the E4 function may be required at all stages of the 
productive cycle (Knight et al. 2004, Doorbar 2006). 
E5 is weakly oncogenic in tissue culture assays and improves the effectiveness 
of the transforming activity of E7 (Bouvard et al. 1994, Valle and Banks 1995). 
The HPV E5 protein is small, hydrophobic and located mainly at the endosomal 
membranes, Golgi apparatus and plasma membranes (Burkhardt et al. 1989, 
Conrad et al. 1993). The protein is probably expressed primarily during the late 
phase of the life cycle to modulate differentiation-induced functions like viral 
amplification and late gene expression (Fehrmann et al. 2003, Auvinen 2005). 
The E6 and E7 proteins are encoded by all papillomaviruses and their ORFs 
are located in the 5’ part of the early region. Together with E7 from high-risk 
HPVs, E6 can induce cellular immortalisation of keratinocytes (Hawley-Nelson et 
al. 1989, Munger et al. 1989). These genes are the main transforming proteins of the 
high-risk HPV types and act by modulating the activities of the cellular proteins 
that regulate the cell cycle. The E6 protein is one of the first genes expressed during 
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HPV infection. It is about 150 amino acids in size and contains two zinc-binding 
domains with the motif Cys-X-X-Cys. The zinc fingers are important for protein 
conformation and interaction with DNA. High-risk E6 proteins are found both 
in the nucleus and in the cytoplasm and have been reported to bind to more than 
12 different proteins (zur Hausen 2002, Whiteside 2008). The E7 protein is rather 
shorter than E6, around 100 amino acids. E7 binds directly to the Rb gene and 
interferes with the ability of Rb to inhibit cell cycle arrest. This allows productive 
replication of HPV genes (Fehrmann and Laimins 2003). 
L1 and L2 proteins that make up the capsid of the virus are synthesised in 
the late phase of the viral cycle. The role of the capsid is to protect the genome 
and to target cellular surface receptors involved in infection. The L1 protein can 
with or without the L2 protein self-assemble into virus like particles (VLP) when 
expressed in eukaryotic cells (Kirnbauer et al. 1992, Stanley et al. 2006). The VLPs 
are morphologically and immunologically comparable to HPV virions. 
There is one part of the HPV genome that does not encode any known protein 
but still has an important function: the long control region (LCR). Its role is to 
regulate gene expression and replication.
Viral life-cycle
The viral replication cycle is one in which viral infection is targeted at basal 
keratinocytes but high level expression of viral proteins and viral assembly occur 
only in differentiating keratinocytes in the stratum spinosum and granulosum of 
squamous epithelium (Doobar 2007, Frazer 2009) . Although our knowledge is 
limited in some key areas of the immunubiology and pathogenesis of the viruses, 
particularly the immediate early events of viral replication, the sequence of events 
shown in Figure 2.3 (see below), in which viral genes are differentially expressed 
both temporally and spatially throughout the infectious cycle, is well accepted 
(Stanley 2006, Wang 2007).
FIGURE 2.3 The HPV infectious cycle (From Stanley 2006)
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The replication cycle takes a long time. Even in the best scenario, the time 
from infection to release of virus will take about 3 weeks since this is the time taken 
for the basal keratinocyte to undergo complete differentiation and desquamate. 
In humans the period between infection and the appearance of lesions is highly 
variable and can vary from weeks to months (Gillison and Shah 2003, Doobar 
2007) indicating that the virus can effectively evade the immune system (Stanley 
2006, Wang 2007).
The replication cycle is exclusively intra-epithelial, there is no detectable 
viraemia, viral gene expression is probably confined to keratinocytes and 
there is no cytolysis or cytopathic death as a consequence of viral replication, 
assembly and release (Stanley 2006). These key events for the virus occur in the 
differentiating keratinocyte, a cell destined for death and desquamation far from 
the sites of immune activity. HPV infection in consequence, is not accompanied by 
inflammation, there is no obvious ‘danger signal’ to alert the immune system—a 
viral strategy that results in persistent, chronic infections as the host remains 
ignorant of the pathogen for long periods.
HPV immunology
The immune system is complex and its responses can vary from person to person due 
to different gene disposition and environmental influences. The majority of HPV 
infected women clear the virus within a rather short period of time. The immune 
response probably has an important role in clearance of the virus. Understanding 
immunity to HPV is important in the development of both prophylactic and 
therapeutic measures against HPV infection and associated cancer.
Antigen presenting cells
Langershans cells (derived from dendritic cells) are the professional antigen 
presenting cells in the epithelium (Campaner et al. 2006). They present the 
endocytosed HPV antigens to T-helper cells by using the MHC class II molecules, 
and thus start up the immune response by secreting and inducing secretion of 
appropriate cytokines from the T-helper cells. Depending on the nature of the 
T-helper cells (Th1 or Th2 type cells) this may lead to enhancement of the cell 
mediated response or antibody response by pertinent cytokines (e.g. γ-interferon 
(IFN) or interleukin (IL)-4, respectively) (Bais et al. 2005, Nguyen et al. 2005). 
Due to viral or environmental factors the Langerhans cells can be depleted from 
the site of HPV infection, which may impair/delay the immune response. Some 
researchers have observed a decrease in the number and functions of Langerhans 
cells in the epithelium of the cervix in women who smoked, suggesting that the 
decrease in the antigen presentation could contribute to the development of CIN 
(Szarewski et al 2001, Arcavi 2004). Smoking is known to induce cytokines Th1 
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and Th2 and may thus have an adverse effect on the immune response (Cozen et al. 
2004, Whetzel et al. 2007, Nakaruma et al. 2008).
Infected epithelial cells may act as (non-professional) antigen presenting 
cells (Stanley 2008). Mostly endogeneous antigens expressed by the genome of the 
infecting virus are presented by the MHC class I molecules to the T-cell receptor. The 
non-professional antigen presenting cells may lack pertinent cell surface molecules 
(e.g. B7) that are needed for cell-cell signalling in conjunction of the antigen 
presentation, and proper stimulation of the cytotoxic T-cells (Doorbar 2007). 
Co-factors of cervical cancer (e.g. C. trachomatis) may induce downregulation of 
these cell-surface molecules by perturbating the local cytokine responses, and thus 
“paralyze” immune response to HPV (Whiteside 2008, Simonetti et al. 2009). 
Most if not all MHC (HLA) class II molecules responsible for antigen 
presentation are capable of presenting peptides derived from the L1 protein of 
HPVs (Zehbe et al. 2005). This is indicated by no genetic defects associated with 
susceptibility to HPV infections, no heterozygosity advance with regard to persistent 
HPV infections or cervical neoplasia, and the fact that 100% of individuals develop 
high titre antibody responses to vaccination after HPV L1 VLP vaccines. On the 
other hand, there exists a genetic predisposition to persistent HPV infection or 
associated cervical neoplasia (Castro et al. 2007). Most likely, however, this is due 
to differences in cytotoxic T-cell responses to the early viral proteins expressed in 
HPV transforme cells – the identified MHC class II associations may be explained 
by linkage disequilibrium with the MHC class I (Liu et al. 2007).  
Antibody responses
The study of antibody responses to HPV is a useful tool in understanding the 
natural history of HPV infection, the cancer association of HPV and for vaccine 
development. Antibodies against L1-containing virus-like-particles (VLPs) are 
HPV type-specific and become detectable 2 to 12 months after infection (Carter 
et al. 1996, Schiller and Hidesheim 2000). Antibodies are not responsible for 
clearance of the virus but are involved in protection against the infection (Wang 
and Hildesheim 2003, Nguyen et al. 2005). The major isotypes of the antibody 
response against HPV are (Immunoglobulin) IgG1 and IgA. Studies on immune 
response to HPV infection showed that serum IgG antibodies persist longer than 
IgA antibodies (Wang et al. 2000). On the other hand, IgA antibodies appear 
early and are markers for recent or active HPV infection, whereas IgG antibodies 
are stable markers of lifetime cumulative HPV exposure (Dillner etal. 1996; af 
Geijersstam et al. 1998, Onda et al. 2003).
Serum IgG against HPV16 is detected in 50 to 60% of women who are positive 
for HPV16 DNA (Kirnbauer et al. 1994, Le Cann et al. 1995, Carter et al. 1996, 
Kjellberg et al. 1999). Most women who seroconvert will do so 6–12 months 
after infection but 10–20% convert during the time HPV DNA is detectable (af 
Geijersstam et al. 1998, Andersson-Ellstrom et al. 1996). When investigating 
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both serum and cervical IgA in women with incident HPV infection, the authors 
observed that within 18 months of the first detection of HPV16, 87.3% of the 
women had developed anti-HPV16 IgA in cervical secretions (Onda et al. 2003).
Women who cleared their infection revert to seronegativity faster than women 
with persistent HPV16 infection (Nardelli-Haefliger et al. 2003). HPV-seropositivity 
has in a few studies been associated with CIN persistence and severity of the lesion. 
Anti-VLP-L1 HPV16 antibodies were detected in approximately 30% of LSIL 
patients, and in 50% of women with HSIL (Sasagawa et al. 1996, Bontkes et al. 
1999, Wideroff et al. 1999). Thus, it is natural that longitudinal seroepidemiological 
studies disclosed that HPV16-seropositive women have an increased risk for 
subsequent development of CC (Lehtinen et al. 1996, Dillner et al. 1997, Lehtinen 
et al. 2001). 
Antibodies against non-structural HPV proteins have also been investigated. 
Anti-E2 IgG was detected in 67% of HPV16 DNA-positive women (Rosales et al. 
2001). Anti-E6 and E7 antibodies can be found in CC patients but are not useful 
as indicators of CC prognosis (Silins et al. 2002). Lehtinen et al. evaluated HPV16 
and 18 E6 and E7 responses in samples taken 1–20 years before time of diagnosis. 
Antibodies were detected in only 7% of women who subsequently developed 
cancer (Lehtinen et al. 2003). Although IgG antibodies to the HPV16 E2 were 
found to be inversely associated with progression of CIN, increased IgA and IgG 
antibody levels to the HPV 18 peptide indicated a significantly increased risk of 
adenocarcinoma (Lehtinen et al. 1992), suggesting that there may be differences in 
the humoral immune response to the major oncogenic HPV types.
Cell-mediated immune response 
Cellular immunity plays a determining role in the early phase of HPV infection and 
is also involved in the immune response to CC (Frazer 2009). Immunohistological 
studies of genital warts and animal models have shown that non-regressing warts and 
lesions are accompanied with very low infiltrates of T cells (CD4+ and CD8+) (van 
der Burg et al. 2007, Kim et al. 2008), langerhans cells (Guess and McCance 2005, 
Caberg et al. 2008), proinflammatory cytokines (Ashrafi et al. 2006, Frazer 2009), 
and that there is a lack of systemic T cell responses to HPV proteins characteristic of 
an adequate regression (Suprynowicz et al. 2008, Fazer 2009). Evidence shows that 
HrHPVs downregulate IFN-inducible gene expression and its signalling pathways 
(Um et al. 2002, Stanley 2008). The Th1-Th2 model of immunoregulation may play 
a role in the natural history of HPV infection. A switch from Th1 to Th2 type 
cytokines has been suggested in cervical carcinogenesis (Frazer 2004, Bais et al. 
2005). Keratinocytes infected by HPV can modify the immune response through 
the production of Th2 cytokines in squamous carcinomas, configuring an evasion 
mechanism against the T-cell mediated immune response (Frazer 2009).
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Experimental studies show that cigarette smoking decreases the secretion of 
proinflammatory cytokines such as IL-1 and IL6 (Arcavi 2004) and suppresses 
IL2 and IFNγ production (Ouyang et al. 2000, Hussain et al. 2008), suggesting 
the possibility that cigarette smoking interacts to increase cervical carcinogenesis 
development.
HPV immune evasion 
HPV infections are slow to induce measurable immune responses or clear, suggesting 
that HPV may have developed methods to evade host immune mechanisms. The 
primary mechanism of viral immune evasion for HPV infection is likely avoidance 
of antigen presentation (Doorbar 2007, Kanodia et al. 2007, Patel and Chiplunkar 
2009). A brief description of different mechanisms involved is presented in Figure 
2.4. 
 
FIGURE 2.4 Human papillomavirus (HPV) immune evasion (Tindle 2002)
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HPV infection and reproduction are totally dependent upon a complete 
programme of keratinocytes differentiation, expressing high levels of viral proteins 
only in the upper layers of the epithelia. Therefore HPV does not induce cytolysis 
or cytopathic death in its host cell but in the virus infected keratinocytes, which 
results in no alarm signal to the immune system and allows persistent and chronic 
infection (Tindle 2002, Kanodia et al. 2007). 
Modes of transmission of HPV infection 
HPV is essentially sexually transmitted (Svare et al. 1998; Centers for Disease 
Control and Prevention 2008). The mean incubation period is estimated to be 2 to 
3 months, ranging from a few weeks to eight months (Handsfield et al. 1997). The 
HPV transmission probability per sexual partnership has been estimated to be 60% 
in mathematical modelling analyses (Barnabas et al. 2006). However, reports of 
high rates of incident, albeit transient, HPV infection in small children have raised 
the issue of alternative modes (mother to child) of acquiring the virus (Stevens-
Simon et al. 2000, Sinclair et al. 2005, Cason and Mant 2005, Puranen et al. 1997, 
Rintala et al. 2005).
HPV detection  
Until recently, the only means of diagnosis of HPV infection was direct or enhanced 
Visual Inspection, a specific but not particularly sensitive method (Denny et al. 
2002, Sarian et al. 2005). The past decades have witnessed the introduction of 
increasingly effective molecular diagnostic techniques for HPV infection.
The Southern Blot method is the basis of all other specific detection methods. 
In this method, DNA is extracted and enzymatically digested. The resulting 
fragments are then separated by electrophoresis according to their size. The isolated 
fragments are denaturated and identified with the help of single-strand fragments of 
complementary DNA or RNA labelled with radioactive or calorimetric molecules. 
This requires relatively large quantities of DNA, is laborious and is impossible to 
automate (Cuzick et al. 1999). 
The Dot Blot method (ViraPap, Viratype) was a simplified version of the 
Southern Blot method that avoids the enzymatic digestion and electrophoresis 
stages. It was partially automated but required large amounts of DNA and had a 
lower sensitivity and specificity (Cuzick et al. 1999).
The filter in situ hybridisation method was also derived from the Southern 
Blot but omitted the DNA extraction step. The target cells were applied directly 
to a solid support and treated to DNA denaturation and identification. While the 
method was simple, it did not perform adequately in clinical use (Demeter et al. 
1987, Cuzick et al. 1999).
In situ hybridization (ISH) demonstrates nucleic acid sequences directly (in 
situ) in the cells. Cells or tissue sections are fixed on a slide and examined under a 
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light microscope enabling the assessment of DNA or RNA localization to be related 
to the morphologic aspects of the lesions. Identification of HPV18 in cervical 
adenoma tissue was confirmed with this methodology (Leminen et al. 1991). ISH 
with biotinylated HPV probes (Syrjänen et al. 1986) is a user friendly version of 
this method. 
The Hybrid Capture Assay I (HC-I) was first introduced by Digene in 1995 
(Clavel et al. 1999). HC-I was a relatively fast, liquid hybridization assay designed 
to detect 9 high-risk HPV genotypes (16, 18, 31, 33, 35, 45, 51, and 56) and one 
of 5 low-risk types (Cuzick et al. 1999). Initially, this was to be used to enhance 
the sensitivity of conventional Pap testing and to provide a meaningful negative 
predictive value for assessing cervical dysplasia. Since then, a second generation 
of Hybrid Capture assay (HC II) has been developed. The assay is a non-reactive, 
chemiluminescence that is easy to perform and can therefore be used in most clinical 
laboratories. The HC II is an effective test that requires less expertise than cytology 
(Terry et al. 2001). HC II detects more HPV genotypes and has high sensitivity and 
specificity (Hesselink et al. 2005, Brink et al. 2007, Kotianiemi-Talonen et al. 2008). 
The intra- and inter-laboratory agreement rates between these methods range from 
good to excellent, i.e. they are well reproducible (Schiffman et al. 2000, Gravitt et al. 
1998, Castle et al. 2004, Kulmala et al. 2004, Carozzi et al. 2005). 
The Polymerase Chain Reaction (PCR) is a selective target amplification assay 
capable of exponential and reproducible increase in the HPV sequences present in 
biological specimens (Brink et al. 2007). The amplification process can in theory 
produce one billion copies from a single double stranded DNA molecule after 
30 cycles of amplification. The sensitivity and specificity of PCR-based methods 
do vary, depending on the DNA extraction procedures, site and type of clinical 
sample, sample transport and storage, primer sets, the size of the PCR product, 
reaction conditions and performance of the DNA polymerase used in the reaction, 
the spectrum of HPVDNA amplified and ability to detect multiple types (Brink 
et al. 2007). Most laboratories use PCR assays which utilize consensus primers 
including GP5+/6+, MY09/11, or SPF primer sets, directed to a conserved L1 gene, 
and hence able to detect all mucosal HPV types. Detection of the hybridized PCR 
product is done by a colorimetric reaction (Gravitt et al. 1998, Kleter et al. 1999) 
or by chemiluminescence (Van der Brule et al. 2002). Recently, a quantitative and 
high-throughput method was developed (Schmitt et al. 2006) based on Luminex 
suspension array technology. This method relies on detection of the consensus 
primer GP5+/6+ products with type-specific oligonucleotide probes coupled 
with fluorescence-labelled polystyrene beads, and allows detection of up to 100 
different HPV types simultaneously. If one is interested in a particular HPV type, 
type-specific PCR can be applied. Confirmation of the specificity of type-specific 
PCRs, as with consensus primer PCRs, can be done by (regular or reverse) filter 
hybridization or by EIA, but also in real-time (Josefsson et al. 1999, Hesselink et al. 
2005, Moberg et al. 2003). The possibility to sequence the amplicons has become 
more and more important in the identification of HPV subtypes (e.g. the African 
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vs. European subtypes of HPV16). Antibodies induced in natural infections by the 
different subtypes cross-react (Pastrana et al. 2004). A great advantage of real-time 
PCR assays is the possibility to quantify the HPV-DNA in the specimen. Several 
studies have shown that the amount of hrHPV present in a cervical smear (the “viral 
load”) as measured by real-timePCR is predictive for the presence or development 
of high-grade cervical lesions (Josefsson et al. 2000, Ylitalo et al. 2000, Van Duin et 
al. 2002, Snijders et al. 2003, Snijders et al. 2006).
Detection of HPV-RNA will in the near future be applied to the distinction 
of transient HPV infections (or mere HPV DNA contamination) from clinically 
significant or persistent infections (Hafner et al. 2007, Khan and Singer, 2008). 
HPV serology measures specific antibodies against different HPV types 
(Carter et al. 1996, Dillner et al. 1996). It is a way of detecting past infection and 
is very suitable for epidemiological studies because serum antibodies are stable 
over time (af Geijerstamm et al. 1998). Type-specific HPV serology has been 
important in the elucidation of the etiological role of HPV and CC (Lehtinen et al. 
1996, Wang et al. 2000, Lehtinen et al. 2001). The most commonly used method 
is enzyme-linked-immunosorbent-assay (ELISA) using HPV virus-like particles 
(VLPs) as the antigen. The standard ELISA detects anti-HPV antibodies of the IgG 
or IgA isotopes. The sensitivity of serology for detecting anti-HPV16 antibodies 
is approximately 50% in best case scenarios, may be up to 65–75%, however, for 
HPV18 it is less than 50% (Kjellberg et al. 1999, Carter et al. 2000). As reported 
early by Kirnbauer and colleagues, IgG anti-HPV antibodies are found in only 
about 60% of women testing positive for cervical HPV DNA (Kinbauer et al. 1994). 
Anti-HPV antibody detection can therefore not be used as diagnostic tool on the 
individual level since all HPV infected women apparently do not seroconvert. HPV 
seropositivity is associated with the numbers of sexual partners and cytological 
lesions (Castle et al. 2002, Dillner et al. 1999).
 
HPV – a necessary cause of cervical cancer
The role of HPV in CC development has been studied in depth, culminating in the 
conclusion that the presence of certain HPV types is necessary for the development 
of CC (zur Hausen 2002, Roden and Wu 2006, Doorbar 2006, Walboomers et al. 
1999, Bosch et al. 2002). Of the numerous HPV viruses, HPV16 is the type most 
commonly found in precancerous and cancerous lesions, followed by HPV18. In 
fact HPV16 and 18, along with 3 other hrHPV types (31, 33 and 45), are responsible 
for 85% of HPV infections that result in CC (Munoz et al. 2003). Other hrHPV types 
associated with CIN and CC are 35, 39, 45, 51, 52, 56, 58, 59 and 66 (with strong 
association) and 26, 68, 73 and 82 (with possible association) (zur Hausen 2006). 
Even though most sexually active women are exposed to HPV infection at least 
once in a lifetime and more than 50% of women worldwide will acquire a genital 
HPV infection (Gunell 2006), development of CC is, however, not common. Thus, 
HPV is not considered to be a sufficient cause of CC. A possible explanation is that 
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other cofactors are also necessary to trigger CC formation. This may be through 
alteration of the host (e.g. immune system), direct carcinogenic potential (creation 
of genotoxic adducts) or direct interaction with HPV in one way or another. 
2.2.3.2 Other sexually transmitted diseases
Conflicting results on the role of herpes simplex virus type 2 (HSV-2) infection 
in cervical carcinoma and its precursors have been reported in several studies. 
HSV-2 may act in conjunction with amplified HPV infection to increase the risk of 
invasive cervical carcinoma (Hildesheim et al. 1991, Olsen et al. 1998, Smith et al. 
2002). Evidence from longitudinal studies, however, indicates no role of HSV-2 in 
cervical carcinogenesis (Ferrera et al. 1997, Lehtinen et al. 2002).
Taking into account the central role of genital HPV infection, C. trachomatis is 
likely to be a risk factor of cervical squamous cell carcinoma (SCC) but its role has 
been difficult to prove (Koskela et al. 2000, Anttila et al. 2001, Wallin et al. 2002, 
Madeleine et al. 2007). Its effect may possibly modulate the host’s immunity and/
or precipitate chronic inflammation as persistence of oncogenic HPV infections 
is more likely among women with a previous C. trachomatis infection (Silins et al. 
2005). 
2.2.3.3  Age
Cancer of the cervix occurs most often in women over the age of 40. The rise in 
incidence of CC begins at ages 20–29, after which it increases rapidly reaching a 
peak between ages 45–49 in Europeans populations. In developing countries, the 
peak is often at a rather later (55–60) age (Curado et al. 2007, Stewart et al. 2003).
In Finland, the incidence of CC has increased especially in fertile-aged women 
during the first years, most likely due to an increase in HPV occurrence (Anttila et 
al. 1999, Laukkanen et al. 2003, Barnabas et al. 2006).
2.2.3.4  Tobacco 
A positive correlation between the incidence of CC and other cancers known to 
be related to cigarette smoking across populations prompted the hypothesis that 
smoking may affect the risk of CC (Winkelstein 1977).
A review of some case-control (Stellman et al. 1980, Clarke et al. 1982, Brinton 
et al. 1986, Cuzick et al. 1996, Parazzini et al. 1998, Hirose et al. 1996) and cohort 
studies (Beral et al. 1988, Tverdal et al. 1993, Zondervan et al. 1996, Tulinius et 
al. 1997, McIntyre-Seltman et al. 2005, Tolstrup et al. 2006) shows that smokers 
have an increased risk of preinvasive neoplasms and invasive squamous-cell CC 
compared to non-smokers. In an earlier IARC evaluation of tobacco smoking, the 
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working group noted that the effect of smoking is confounded by sexual behaviour 
variables, but the data were not adequate to remove the confounding effect, and 
that a reasonable conclusion from the available studies of invasive CC is that the 
results, although they indicate a positive effect of smoking, are compatible with 
the residuals effects of variables that play a fundamental role in the aetiology of 
CC (IARC 1986). The extent to which the relationship between smoking and CC 
reflected a causal association independent of infection with HPV remained a cause 
of concern. It was believed that the association of smoking with CC may be causal, 
may even reflect causality via an effect of smoking on risk for HPV infection, or 
may reflect confounding or risk modification among women with HPV infection 
(IARC 1996).
In a few cohort studies (Deacon et al. 2000, Castle et al. 2002, McIntyre-
Seltman et al. 2005, Mosciki et al. 2001) and case-control studies (Chichareon et al. 
1998, Ngelangel et al. 1998, Munoz et al. 1993, Ho et al. 1998, Yoshikawa et al. 1999, 
Kjellberg et al. 2000, Gunnell et al. 2006) reporting on the association between 
smoking and CIN or ICC, the point estimates were adjusted for HPV DNA status. 
In these studies, the association between CC and smoking was not eliminated even 
though most studies additionally controlled for several well-established risk factors 
for CC. Women who smoked for a long period or who smoked heavily generally 
had the highest risk. In several of these studies, the relation was restricted to, or 
strongest among, recent or current smokers. The highest point estimates were 
observed among women who had started smoking early in life (La Vecchia et al. 
1986, Daling et al. 1996, Plummer et al. 2003). 
Several cohort studies (Deacon et al. 2000, McIntyre-Seltman et al. 2005, 
Tolstrup et al. 2006) and case-control studies (Bosch et al. 1992, Eluf-Neto et al. 
1994, Chaouki et al. 1998, Olsen et al. 1998, Ho et al. 1998, Santos et al. 2001, Rolon 
et al. 2000, Castle et al. 2002, Shields et al. 2004, Rajeeran et al. 2005), including 
the IARC multicentre pooled analysis of 10 studies of invasive CC (Plummer et al. 
2003), examined tobacco smoking as a co-factor to HPV infection by restricting the 
analysis to HPV DNA-positive study participants. The results from these analyses 
showed no significant alteration in risk whether or not the study participants were 
HPV DNA-positive. A nested case–control study of CIN 3 investigated the effect 
of smoking among HPV-seropositive cases and controls and found that the effect 
of smoking remained, and there was evidence of a dose-response relationship 
(Deacon et al. 2002).
No association between smoking and adenocarcinoma and adeno-squamous-
cell carcinoma of the cervix has been observed (Brinton et al. 1986, Ursin et al. 
1996, Chichareon et al. 1998, Ngelangel et al. 1998, Madeleine et al. 2001).
Tobacco chewing has rarely been studied as a risk factor of CC. To date, only 
one study has reported an association between tobacco chewing and increased risk 
of invasive CC in Southern India (OR = 4.0, 95% CI 1.2–13.3) (Rajkumar et al. 
2007).
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Smoking has been associated with persistent HPV infections (Szarewski et al. 
2001) and decreased clearance of CIN lesions (Szarewski et al. 1996). Reduction 
in lesion size was highly correlated both with the reduction in reported amount 
of smoking and with the final-visit cotinine measurements (Szarewski et al. 1996). 
Whether the link between smoking, HPV and CC is related to: 1) Genotoxic 
adducts of tobacco in the cervix epithelium (Ali et al. 1994, Phillips et al. 1994, 
Prokopczyk et al. 1997), 2) Effects on HPV transformation (Motoyama et al. 
2004), or 3) Localised immunosuppression (Poppe et al. 1995), has been discussed. 
Tobacco-specific carcinogens and polycyclic aromatic hydrocarbons have been 
identified in the cervical mucus or epithelium of smokers (Melikian et al. 1999, 
Prokopczyk et al. 1997). These compounds can damage cellular DNA and may 
cooperate with HPV to produce malignant transformation (Simons et al. 1995). 
Finally there is also evidence that some studies have tried to show the effects of 
the harmful substances absorbed by the human body during the act of smoking 
in the immunological defence of the cervical epithelium. Current smokers have 
significantly lower Langherlans cell counts than nonsmokers in normal cervical 
epithelium and in CIN, HPV infection, or both (Poppe et al. 1995). 
2.2.3.5  Immune compromization
Women infected with the human immunodeficiency virus (HIV), the virus that 
causes AIDS, or who have used medication that suppresses the immune system 
have an excess risk of developing CC. CC is one of the “AIDS-indicative diseases”. 
Higher risk of HPV infection and lower HPV clearance have been observed in 
women infected with HIV than in uninfected women (Palefsky et al. 1999, Ho 
et al. 1998, Rowhani-Rahbar et al. 2007). Furthermore, the high prevalence, 
incidence and persistence/progression of SILs appear to be associated primarily 
with increased HPV persistence that may result from immunosuppression related 
to HIV infection (Hawes et al. 2006, Six et al. 1998). 
Long-term immunosuppression seems to increase the risk of CC among other 
anogenital cancers: in a few population-based follow-up studies, the observed 
incidence of cervical cancer among renal transplant patients has been higher 
than the expected rate (IARC 2006). In a study conducted in Australia and New 
Zealand, the age-standardised incidence ratio in transplant recipients was 3.3 after 
a mean follow-up of 5.8 years, whereas, it was 0.74 for dialysis patiens (Fairley et 
al. 1994). In a register-based study from the Nordic countries, the standardised 
incidence ratio for cervical cancer in transplant recipients was increased after an 
average of 4.8 years of follow-up (Birkeland et al. 1995). The increase was most 
notable in fertile-aged women among whom impaired immune system probably 
allows persistent HPV infection.
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2.2.3.6  Other risk factors
There is evidence that numerous other risk factors such as irregular or total lack 
of screening (Bosch et al. 1992, Leyden et al. 2005, Nygard et al. 2002), number of 
sexual partners (Biswas et al. 1997, Kjaer et al. 1992, Agarwal et al. 1993, Bosch et 
al. 1996, Castellague et al. 2002, Franceschi et al. 2003, Hammouda et al. 2005), 
long term oral contraceptive use (Appleby et al. 2007, Smith et al. 2003), multiparity 
(Autier et al. 1996, Franceschi et al. 2003, Hammouda et al. 2005, Munoz et al. 
2002), early age of sexual debut (Biswas et al. 1997, Bosch et al. 1992, Ferrera et 
al. 2000), low socio-economic status and ethnicity (de Sanjose et al. 1997, Ries et 
al. 2008), micronutrients deficiency (Garcia-Closas et al. 2005, Potischman et al. 
1996), genetic susceptibility (Zelmanowicz et al. 2005, Magnusson et al. 1999) may 
increase the risk of CC. Highest risk estimates were observed among women with 
HPV infection.
2.2.4  Prevention  
2.2.4.1  Screening and HPV testing
The objective of cervical screening is to prevent invasive CC by detecting and 
treating women with high-grade SIL i.e CIN 2 and 3 lesions. 
Conventional cytology (Pap smear) screening entails collection of cervico-
vaginal epithelial cells using a wooden spatula or a brush, preparation and fixation 
of the smear. Screening with conventional cytology has resulted in a marked 
decrease in cervical cancer incidence and mortality in a number of countries. 
However, in some countries the effect of screening has been virtually nonexistent 
(International Agency for Research on Cancer 2005). In addition to the lack of 
organisation, the blame has often been laid on the quality of conventional cytology. 
Worldwide, the variation in the accuracy of conventional cytology is wide: estimates 
for the sensitivity for CIN 2+ vary from about 30% to 90% and, respectively, for the 
specificity from 85% to nearly 100% (Soost et al. 1991, Nanda et al. 2000, IARC 
2005, Arbyn et al. 2008c). Reproducibility of conventional cytology measured 
through intra and interobserver variability has been at best moderate to good 
(Branca et al. 1996, Cocchi et al. 1997, Branca et al. 1998, Woodhouse et al. 1999, 
Gupta et al. 2001, Chhieng et al. 2002).
Organised cytology screening with systematic call, recall, follow-up and 
surveillance systems has shown the greatest effect (e.g. Finland) (Nieminen et al. 
2004; Kotaniemi-Talonen et al. 2007). Failure and difficulties in organizing Pap 
smear screening in low- and medium-resourced countries have prompted the 
search for and evaluation of alternative screening test such as visual screening after 
the application of acetic acid (VIA) or Lugol’s iodine (VILI) and HPV DNA testing 
(IARC 2004, Sankaranarayanan et al. 2005a).
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Liquid-based cytology (LBC) is a modification of conventional cytology that 
is widely used for primary CC screening. With this technology cervical samples are 
collected into liquid solution, which is then used for cytological slide preparation. 
The residual material may be used for additional testing, e.g. HPV DNA detection. 
Several LBC tests are commercially available, among which ThinPrep (by Cytyc 
Corporation) and the BD SurePath System (formerly AutoCyte PREP System, 
by BD Diagnostics, Diagnostic Systems – TriPath) are the best-known and most 
studied (Arbyn et al. 2008a). 
Recent randomised studies and meta-analyses have shown that the 
performance of LBC in terms of CIN 2+ detection is comparable to conventional 
cytology (Davey et al. 2006, Ronco et al. 2007, Arbyn et al. 2008b). However, some 
studies have reported a smaller number of unsatisfactory smears with LBC than 
with conventional cytology, and the time needed for interpretation is possibly 
shorter with LBC (Colgan et al. 2004, Dowie et al. 2006, Doyle et al. 2006, Ronco 
et al. 2007). 
The fact that cervical neoplasia are caused by persistent infection with 
oncogenic types of HPV has led to the evaluation of HPV testing as a primary 
screening and/or secondary test for cervical neoplasia. The optimal age for HPV 
testing is likely to be between 30-40 years i.e. before the risk of CC starts to increase. 
HPV testing is the most objective and reproducible of all currently available 
cervical screening tests. The sensitivity of HPV testing in detecting CIN 2 and 3 
lesions varied from 66 to 100% and the specificity varied from 62 to 96% in several 
cross-sectional studies (Franco 2003, Koliopoulos et al. 2007, Sankaranarayanan 
et al. 2005). In randomized trials, the sensitivity of HPV test for the detection of 
CIN is greater than that of Pap testing (Kotaniemi-Talonen et al. 2005, Bulkmans 
et al. 2007, Mayrand et al. 2007, Naucler et al. 2007, Sankaranarayanan et. al. 2009). 
A pooled data from seven European perspective screening studies shows that the 
cumulative incidence of CIN3/cancer was 0.27% among women negative for HPV 
DNA, whereas the respective cumulative incidence among women with negative 
cytological test was significantly higher, 0.97% (Dillner et al. 2008). 
Self-collected samples for testing of oncogenic HPV is a potentially viable 
screening option that holds promise for women in under-resourced areas or those 
who are reluctant to participate in screening programmes, save for the limited 
evidence supporting it (Stewart et al. 2007). 
2.2.4.2  Vaccination
While early detection of asymptomatic precancerous lesions by screening and 
their effective treatment leads to the prevention of ICC and premature death, the 
fact that CC is caused by persistent infection by one or more of the 15 oncogenic 
HPV types, with HPV types 16 and 18 causing more than 70% of cervical cancers, 
provides the exciting opportunity for prevention through vaccination.
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Vaccinations with virus VLP were first found to be safe and highly protective in 
animal models. Rabbits that were immunized with cotton-tail rabbit papillomavirus 
(CRPV) VLPs were protected upon CRPV challenge and neutralizing antibodies 
were detected in most of these studies (Breitburd et al. 1995, Jansen et al. 1995). 
Currently, two vaccines against human papillomavirus infection are 
commercially available,bivalent CervarixTM (by GlaxoSmithKline) and quadrivalent 
GardasilTM (by Merck and Co. Incorporation). Both vaccines are made from L1 
VLPs i.e. empty protein shells resembling the real virus, for which they are non-
infectious. Both vaccines are targeted against HPV types 16 and 18 that are 
estimated to cause altogether 70% of cervical cancers worldwide (Muñoz et al. 
2004). In addition, Gardasil additionally targets two low-risk HPV types, HPV6 
and 11 that cause 90% of genital warts. 
VLP vaccines to prevent papillomavirus infections in humans have been 
evaluated in several studies (phase I to phase III) (Harper et al. 2006, Koutsky et 
al. 2002, Koutsky and harper 2006, Villa et al. 2006, The Future II Study Group 
2007, Paavonen et al. 2007). The results from these studies indicate that HPV VLP 
vaccines are highly immunogenic in early adolescents (aged 9–13) and young 
women. The antibody titres are 2-fold higher among prepubertant boys and girls 
than among young women aged 16–26 years (Villa et al. 2005, Pedersen et al. 
2007, Reisinger et al. 2007, Block et al. 2007, Dawar et al. 2007, Petäjä et al. 2009). 
This is in concordance with high immuno-response of other vaccines in children 
(Reisinger et al. 2007). In phase II clinical trial, quadrivalent HPV6, 11, 16 and 18 
L1 VLP-induced antibody titres reach their highest level 7 months following the 
first vaccine dose. The titres then decline, reaching a plateau 18–24 months later. 
This plateau is maintained for at least 5 years, with 5-year levels that are similar to 
the titres naturally induced by HPV types 6 and 18 and that are higher than the 
titres naturally induced by HPV types 11 and 16 (Villa et al. 2006). At 24-month 
follow-up, over 96% of participants in the HPV vaccine group were seropositive 
for HPV types 6, 11 and 16; however, only 68% of participants were seropositive 
for HPV type 18. The significance of this reduction remains unclear as immune 
memory is induced by the vaccine (The Future II Study Group 2007). This has not 
been noted with the AS04-adjuvanted bivalent HPV16/18 vaccine (Harper et al. 
2006). Geometric titers (GMTs) for vaccine induced antibodies against HPV16 or 
HPV18 infections were substantially higher (≥11-fold) than those seen in natural 
HPV16 or HPV18 infections at all timepoints over 5.5 years (Harper et al. 2006). 
High seroconversion rates and strong vaccine-induced antibody response were also 
evident in the interim (14.8-month) results of the papilloma trial against cancer 
in young adults (PATRICIA) study, a large phase III trial of the AS04-adjuvanted 
HPV16/18 vaccine. At month 7, peak GMTs were 313-fold (HPV16) and 211 
(HPV18) higher than corresponding values in women who had cleared natural 
HPV16/18 infections (Paavonen et al. 2007).
The results from vaccine efficacy (phase III) trials have shown high efficacy 
against HPV 16 and 18-related CIN 2/3 and adenocarcinoma in situ lesions among 
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adolescents and young women naïve for these HPV types and received at least 
one dose (of the three recommended) of the vaccine. The quadrivalent vaccine 
prevented 100% of HPV16 and HPV18-related cases of high grade (grade 2/3) 
vulvar or vaginal neoplasia, and 95% of HPV6, 11, 16, 18-related cases of CIN 
(grade 1, 2, 3) (The Future II Study Group 2007). The AS04-adjuvanted HPV16/18 
vaccine demonstrated 90%–100% efficacy in preventing CIN 2+ and 89% efficacy 
in preventing CIN 1+ associated with HPV16/18 infections (Paavonen et al. 2007, 
Paavonen et al. 2009). Results from the phase II trial showed that the HPV16/18 
vaccine efficacy was 100% in terms of preventing HPV16/18-associated CIN 1+ or 
CIN 2+ after at least 5.5 years of follow-up (Harper and Dubin 2007) .
 HPV vaccination holds great promises for CC prevention, but there are still 
several issues that need to be resolved before it can be widely implemented in 
high-risk developing countries (Agosti et al. 2007). These include: current high 
costs of the vaccine, affordability, feasibility, acceptability, logistics of vaccine 
delivery (in view of the needs for three doses spread over 6 months, improved 
strategies and vaccine platforms to reach out to pre- or early-adolescent girls), 
long–term immunogenicity and efficacy in preventing cervical neoplasia, cross-
protection against HPV types not targeted by the vaccine antigens and the efficacy 
of different, more logistically feasible dose regimes in including and maintaining 
immunogenicity and long term protection against cervical neoplasia. To initiate 
HPV vaccination in low- and medium-resource countries, vaccination costs should 
be dramatically reduced both by lowering the costs of the vaccine and of vaccine 
delivery. 
A population-based phase III study in Finland will consider the long-term 
outcomes in HPV16/18-vaccinated adolescents versus those receiving a control 
vaccine or no HPV vaccine at all (Lehtinen et al. 2006). While prophylactic 
vaccination is likely to provide important future health gains if vaccination is 
offered to girls before onset of sexual activity, cervical screening should still be 
continued for women, as the risk of being already infected with the oncogenic HPV 
types remains. For the vaccinated birth cohorts the mode of screening most likely 
will change in years to come.
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3 Aims of the study
The general purpose of this work is to contribute to understanding the role of 
smoking in the natural history of HPV infection and its progression to CC. 
The specific aims were:
1.  To ascertain whether the association between smoking and CC is due to an 
independent role of smoking or due to residual confounding by oncogenic 
HPV types.
2.  To compare the association between tobacco chewing in Côte d’Ivoire, West 
Africa and tobacco smoking in Finland, Northern Europe, and the age-
stratified risk of multiple HPV infections and cervical SIL.
3.  To evaluate the role of smoking in the impairment of the immune response 
following natural HPV16 and HPV18 infection.
4.  To evaluate the role of smoking in immune response following immunization 
with adjuvanted HPV16/18-AS04 VLP vaccine.
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4 Materials and methods
4.1  Data sources and study participants
4.1.1  The Nordic population-based biobanks (Paper I)
4.1.1.1  Characteristics of the serum banks
Five population-based serum banks collaborated in this nested case-control study: 
the Finnish Maternity Cohort (FMC), the Iceland Maternity Cohort (IMC), the 
Northern Sweden Maternity Cohort (NSMC), the Northern Sweden Health and 
Disease Study (NSHDS) and the JANUS Project in Norway.
The FMC was established in 1983. By 2006 it comprised around 1,300,000 
serum samples collected from 750,000 women, practically all pregnant women 
attending maternity clinics during the first trimester of pregnancy. The samples 
are stored at -25˚C at the National Institute for Health and Welfare laboratories in 
Oulu, Finland (Pukkala et al. 2007).
The nation-wide IMC contained 96,000 serum samples, by 2003, collected 
from 50,000 women at 12 to 14 weeks of pregnancy for rubella screening. The 
samples have been stored since 1980 at -20˚C in the Department of Medical 
Virology, Landspitali University Hospital, Reykjavik, Iceland (Pukkala et al. 2007). 
The NSMC consists of sera collected since 1975 from pregnant women 
screened for rubella immunity during week 14 of pregnancy in Västerbotten county 
and especially in the 1980s for some of the adjacent counties in Northern Sweden. 
So far, almost 120, 000 samples from 86,000 women have been stored at -20˚C at 
the virus laboratory of Umeå University, Sweden (Pukkala et al. 2007).
The NSHDS contains the Monitoring Trends and Determinants in 
Cardiovascular Disease (MONICA) cohort and the Västerbotten Intervention 
Program (VIP). The MONICA project contains material from population-based 
screenings for cardiovascular diseases carried out in 1986, 1990, 1994, 1999 and 
2004. There are 14,000 sampling occasions of 9,000 individuals, 50% of whom are 
included in VIP. Established in 1985, the VIP is a long-term project intended for 
health promotion and including 74,000 individuals by 2004, of whom 70,000 had 
donated blood samples. The samples are collected annually from all residents aged 
40, 50 and 60 years of age, in the Västerbotten county, northern Sweden, and stored 
as plasma at -80˚C at the University Hospital of Umeå, Sweden (Pukkala et al. 2007, 
Tedeschi et al. 2006).
The JANUS serum bank was established in Oslo, Norway in 1973 to identify 
early changes in chronic disease development. In 2003 the JANUS serum bank had 
430,000 serum samples from 331,801 donors, 10% of them are Red Cross blood 
donors. About 145,000 female donors have been recruited during routine health 
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examinations in subsequent phases. Serum samples in 1974–1978 and in 1983–
1991, are being stored at -25˚C (Pukkala et al. 2007).
4.1.1.2  Population-based cancer registries
The cancer registries of Finland, Iceland and Norway and the regional cancer registry 
in Umeå, Sweden are all population-based and country-wide (four northernmost 
Swedish counties for Umeå). Audits have shown that virtually all cases of cancer 
are being reported to the cancer registries by physicians and pathology/hematology 
laboratories, and 95% of them are histologically confirmed (Engeland et al. 1995). 
Following approval of the appropriate ethics committees, serum banks were linked 
to the national cancer registries using the unique personal identification number 
(PIN) available in the Nordic countries for each citizen.  
4.1.1.3  Identification of cases and controls 
To elaborate the association of smoking and CC, we performed two consecutive 
nested case-control studies (Studies I and II, based on 171 and 588 invasive CC 
cases matched respectively to 496 and 2861 unaffected controls). Study I had 
limited power to distinguish whether smoking was an independent co-factor in 
cervical carcinogenesis and in Study II, we assembled almost four times as large 
independent material. Most of cases in Study I were included in Study II (Table 
4.1). 
Cases were women diagnosed with invasive CC following their enrolment into 
one of the Nordic cohorts. Cases were identified by linking the serum bank data 
files with the national cancer registries. When serial blood samples were available, 
the first sample collected with the longest lag time to cancer diagnosis was chosen. 
Controls were selected from the same serum bank as cases (Table 4.1). For 
each case, five female controls who were alive and free of cancer at the time of the 
case’s diagnosis were randomly selected and matched for age at serum sampling (± 
2 years), storage time (± 2 months) and for county in Norway and Sweden. If five 
controls could not be found, matching criteria of age at blood collection and length 
of frozen storage were widened. 
The average lag times from serum sampling to cancer diagnosis was 4.7 years 
in Study I and 9.6 years in Study II. In Study I, the mean ages at diagnosis were 
as follows, the FMC: 34 years, the JANUS health examinations: 47 years, Norway 
(1974–1978): 46 years, Norway (1981–1992): 47 years and the NSHDS: 50 years. In 
Study II, the mean ages at diagnosis were as follows, the FMC: 38 years, the JANUS 
health examinations: 49 years, Norway (1974–1978): 56 years, Norway (1981–
1992): 47 years, the JANUS Red Cross blood donors: 44 years, the NSMC: 37 years 
and the IMC: 34 years.
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TABLE 4.1 Characteristics of the Nordic cohort for a nested case-control study of the cervical carcinoma risk associated with previous exposure to tobacco 
smoke.
Serum bank Geographic location Period 
of serum 
sampling
Female serum 
sample
donors (no.)
by the end of 
year 2003
Cases 
(no. in Study 
I/ Study II)
Controls 
(no. in Study 
I/Study II)
Age at 
diagnosis 
(years) in 
Study I/Study 
II
Janus Project
Northern Sweden Health and 
Disease Study (VIP & MONICA)
Northern Sweden
Maternity Cohort
Finnish Maternity
Cohort
Icelandic Maternity Cohort
Total
Three counties in Norway
Several counties in Norway
Red Cross blood donors in 
capital
Two northernmost counties in 
Sweden
Four northernmost counties in 
Sweden
Finland
Iceland
Nordic countries
1974–1978
1981–1992
1973–1991, 
1997–2000
1985–present
1975–present
1983– present
1980– present
1973– present
 29,000
115,000
14,000
 
38,000 
86,000
681,000
49,000
1,008,000
79/36
47/129
–/45
4/–
–/111
41/167
–/100 
 
171/588
237/178
141/639
–/223
12/–
–/530
106/798
 
 
–/493 
 
496/2861
26–63/32–70
35–63/29–67
   –/29–69
39–60/–
   –/21–57
22–49/22–54
    –/23–55
22–63/21–70
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4.1.2  The DYSCER – Côte d’Ivoire study (Papers II)
The disease screening research study (DYSCER) was conducted from April 1995 
to February 1996. The study took place in three outpatient gynaecology clinics of 
Abidjan, Côte d’Ivoire. Women attending the clinics were eligible for the study if 
they fulfilled the following inclusion criteria: age between 20 and 50 years, absence 
of history of lower genital tract neoplasia, and absence of active pregnancy. A 
questionnaire was administered to each participant to obtain information on 
tobacco use. The subjects underwent pelvic examination and the cervical Pap smears 
obtained were independently read twice, in Abidjan and in France, in order to 
minimize false negative/positive results. Colposcopy with biopsies was performed 
on women with HSIL. Cases included all women with cytological cervical SIL. 
Controls were chosen at random during the same time and in the same clinics 
among the women without cytological cervical lesions with a frequency matching 
for age (by decade) and center. A complete description of this material has been 
published previously (La Ruche et al. 1998).
4.1.3 The KUOPIO Cohort (Paper II, III)
A prospective follow-up study of 532 women (mean age 28.7 years, range 15 to 
69 years) with cervical HPV infection was conducted at the Kuopio University 
Hospital, Kuopio, Finland between 1981 and 1992. The original aim was to establish 
prognostic factors associated with the clinical course of HPV infections identified 
in young women by cytology. The cohort participants were recruited among women 
whose routine Pap smear showed unequivocal changes of HPV infection, i.e., 
koilocytotic cells with or without dyskaryotic abnormalities. The participants were 
subjected to a thorough gynecological examination including colposcopy, repeat 
Pap smear, and directed punch biopsy (when clinically indicated). A questionnaire 
was also administered to each woman to obtain information on medical history 
and smoking habits. After the first visit, all the participants were scheduled to 
attend the gynecological outpatient clinic of the Kuopio University Hospital for 
follow-up visits at 6-month intervals. Cervical smears and serum samples were 
collected at each visit. A complete description of this material has been published 
previously (Kataja et al. 1992). 
The comparative study (Paper II) included 2162 women (mean age 29.4 ± 7.1 
years, range 20–50 years) from Côte d’Ivoire and 419 women (mean age 27.8 ± 7.9 
years, range 15–49 years) from Finland with complete baseline data on HPV status, 
tobacco use, Chlamydia trachomatis infection and HIV status.
In Paper III, we collected data from the Kuopio Cohort. A total of 191 
participants (mean age 27.5 ± 6.9 years, range 16-49 years) who had available HPV 
DNA biopsy data at the end of the follow-up, and for whom at least two serum 
samples (first and last samples of the follow-up) were available for serology and 
cotinine analyses, were included in the analyses.
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These study protocols were each approved by the respective ethics committee 
in Côte d’Ivoire, France and Finland.
 
4.1.4  The PATRICIA Study (Paper IV)
Enrolment for the papilloma trial against cancer in young adults (PATRICIA) study 
took place from April 2004 to May 2005 in Finland. Healthy women aged 16–17 
years were eligible to participate in the Finnish arm of this study with no exclusion 
criteria with regard to lifetime sexual partners before study enrolment. Individuals 
with intact cervix and agreeing to adequate contraception (barrier methods in 
combination with a spermicide or hormonal contraception) over the vaccination 
period were eligible for inclusion. Exclusion criteria were limited to women with a 
history of colposcopy, who were pregnant, or breastfeeding, or who had chronic or 
autoimmune disease or immunodeficiency. 
Informed consent was obtained from each participant to the performance of 
any study procedures. All recruitment materials, informed consent/assent forms, 
protocols and amendments were approved by the Finnish National Ethical Review 
Committee. This study is registered with the European Clinical Trials Database. 
This was a phase III double-blind, randomized controlled trial. In Finland, a 
total of 4,808 participants were randomised in a 1:1 fashion with an internet-based 
centralized randomisation system received either the AS04-adjuvanted HPV16/18 
vaccine (GlaxoSmithKline Biologicals, Rixensart, Belgium) or, a control hepatitis 
A vaccine (GSK Biologicals), to provide a health benefit for all participants and 
ensure double-blinding. Allocation of treatment numbers was stratified by study 
site and by age. Because the study is gradually ending, a random sample of 216 
study participants with individual vaccine allocation unblinded, wase selected 
from the three biggest Finnish study sites: the Finnish Family Federation, Helsinki, 
the University of Helsinki, Helsinki and the University of Tampere, Tampere for 
this study.
Each dose of HPV-16/18 L1 VLP AS04-adjuvanted candidate vaccine 
(CervarixTM) contained 20 mg each of HPV-16 and -18 L1 proteins self-assembled 
as VLP and adjuvanted with AS04 (50 mg 3-O-desacyl-40-monophosphoryl lipid 
A [MPL] and 500 mg aluminum hydroxide). The vaccine was produced using a 
Baculovirus Expression Vector System in which each type of VLP antigen was 
produced on a Hi-5 cell line derived from Trichoplusia ni. Each dose of the control 
hepatitis A vaccine contained 720 ELISA units (EU) of inactivated hepatitis 
A antigen and 0·5 mg aluminium hydroxide. The vaccines were supplied under 
double-blinding in identical 0·5 ml prefilled syringes and administered into the 
deltoid muscle on a 0, 1, and 6-month schedule. According to protocol the code 
was broken for the subset selected for this study in March 2009. 
Blood samples were collected at baseline and at month 7 post-vaccination, 
and stored at the National Institute for Health and Welfare laboratories in Oulu, 
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Finland from each participant before the first vaccination and at month 7 to assess 
vaccine-induced immune responses to HPV16, HPV18 or related factors.
Participants completed and returned safety diary cards documenting 
symptoms experienced during the first 7 days after vaccination and symptoms 
within the first 30 days after vaccination as previously described (Paavonen et al. 
2007). 
4.2  Laboratory methods
For all the studies, the laboratory analyses were performed on coded specimens, 
with case-control status masked. The samples of a case and her matched controls 
were pipetted on the same microplate.
4.2.1  Cotinine detection (Papers I to IV)
Blood samples were measured for cotinine using a qualitative immunoassay 
method (OraSure Technologies, Bethlehem, Pennsylvania) that is carried out as 
a quantitative assay and is based on the competition between free cotinine in the 
sample and cotinine bound to horseradish peroxidase-labelled cotinine. Cotinine 
concentration was quantified by measuring the light absorbance of wavelengths of 
450 nm and 630 nm and by comparing the cotinine concentration of each sample 
with the standard curve. This assay has a sensitivity of 95%–97% and a specificity 
of 99%–100% (Murray et al. 1993, Parish et al. 1995, Pérez-Stable et al. 1995). 
Careful testing of this method has revealed excellent correlations with established 
gas chromatography (Feyerabend et al. 1990) and radioimmunoassay (Knight 
et al. 1985). Regression dilution bias was assessed by measuring paired samples 
repeatedly with the same batch from the assay kit (Clarke et al. 1999).
4.2.2  HPV serology and detection (Papers I to IV)
The presence of IgA (Paper III) and G (Paper I, III, IV) antibodies specific for 
HPV types 16 and 18 was determined by means of a standard enzyme-linked 
immunosorbent assay (ELISA) as reported elsewhere (Dillner et al. 1996; Lehtinen 
et al. 2006). For the IgA assay, goat anti-human IgA HRP conjugate antibody 
(Novus Biologicals, Colorado, USA) was used for detection. IgG analyses were 
done applying VLPs kindly provided GSK Biologicals. 
We employed baculovirus-expressed capsids comprising both the L1 and L2 
proteins, with disrupted capsids of bovine papillomavirus used as the negative 
control. The specificity of HPV serology was found to be high, since no antibodies 
could be found in serum samples from virginal women and seropositivity had 
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a linear relation to lifetime number of sexual partners (Dillner et al. 1997). The 
sensitivity of HPV serology for detecting past HPV infection has been estimated to 
vary between 50% and 70% (Carter et al. 1996, Kjellberg et al. 1999). Seropositivity 
was defined as a titer greater than or equal to the assay threshold for HPV16 and 
HPV18. Dilutions 1/30, 1/300 and 1/3000 were used to identify the linear part of 
the absorbance reactions for expression of the results as OD values.
HPV DNA was detected using PCR (Côte d’Ivoire) (Paper II) and ISH 
(Finland) (Papers II and III) techniques. In Côte d’Ivoire, cervical specimen for 
HPV detection were collected with a plastic brush (Viba-Brush, CML, Nemours, 
France), placed in a transport medium (sterile RPMI 1640 medium supplemented 
with penicillin and fungizone), and frozen at -80˚C until testing. The presence of 
cervical HPV was tested in 547 participants including 224 women with cervical SIL 
(151 LSIL, 60 HSIL, and 13 cervical cancer cases) and 323 controls. HPV DNA was 
detected with a polymerase chain reaction (PCR)-based method using HPV L1 
consensus primers (MY11 and MY09) affording the detection of a broad spectrum 
of genital HPV types as previously described (La Ruche et al. 1998). 
For HPV DNA-positive samples, restriction fragment length polymorphism 
analysis of the amplimers produced during PCR was used to determine HPV types 
6, 11, 13, 16, 18, 31, 33, 34, 35, 39, 40, 42, 44, 45, 52, 53, 56, 58, 59, 61, 62, 64, 66, 
67, 68, 70, 71 (CP8061), 81 (CP8304), 82 (MM4 et IS39), 83 (MM7), 84 (MM8). 
Only samples that gave a strong enough signal to be detected clearly on gels after 
enzymatic digestion were considered for HPV typing. In Finland, formalin-fixed, 
paraffin-embedded biopsies from all patients were analysed using DNA-ISH 
technique with S- and biotinylated HPV DNA probes as described earlier (Syrjänen 
and Syrjänen 1986). Specific DNA probes for HPV types 6, 11, 16, 18, 31, and 33 
were used. The presence of HPV DNA sequences in the lesions was indicated by 
dense condensations of black–silver grains, usually superimposed on the nuclei of 
the intermediate and superficial cells, in HPV lesions.
4.2.3  Chlamydia trachomatis serology (Papers I, II and III)
The presence of IgG antibodies specific for C. trachomatis was determined by the 
microimmunofluorescence (Hanna et al. 1980) (Paper I) and ELISA (Dillner et al. 
1999) (Paper II, III) methods according to the manufacturer’s instructions. 
4.2.4  HSV-2 serology (Paper I)
The presence of IgG antibodies HSV-2 was also determined using a commercially 
available HSV-2 glycoprotein gG-2-based ELISA (Biokit SA, Barcelona, Spain) 
according to the manufacturer’s recommendation (Lehtinen et al. 2002).
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4.2.5  HIV (Paper II)
All sera from Ivorian women were screened in Abidjan by ELISA (Genelavia Mixte, 
Sanofi Diagnostics Pasteur, Paris, France). In Finland, there were no HIV-positive 
women diagnosed in the catchment area of Kuopio University Hospital between 
1981 and 1986 (National Institute for Health and Welfare, Finland 2007).
4.3  Statistical methods
Paper I
The cotinine level that is accepted as defining an active smoker depends on the 
prevalence of smoking in the population (Murray et al. 1993, Cummings and 
Richards 1988). In this paper, the measured cotinine levels were categorized into 3 
groups: less than 20 ng/mL for nonsmokers or persons passively exposed to tobacco 
smoke and 2 other categories of 20-<100 ng/mL and ≥100 ng/mL, corresponding 
approximately to average levels found among light and heavy smokers. 
Relative risks, expressed as odds ratios (ORs), were estimated using conditional 
logistic regression for matched case-control sets of cervical cancer by means of 
GLIM4 (Numerical Algorithms Group, Oxford, United Kingdom) (Breslow and 
Day, 1980). The 95% confidence intervals (CIs) for the ORs were based on profile 
likelihood (Nelder, 1990). Heterogeneity in the point estimates was assessed with 
a likelihood ratio test. The nested models compared were one for overall effects of 
cotinine groups (20-<100ng/ml and ≥100 ng/ml) and the other one also including 
serum bank-specific effects of the cotinine groups. Unconditional logistic regression 
was applied to HPV16/18-seropositive cases and controls, including the matching 
variables (serum bank, subcohort, storage time and age at serum sampling) in the 
model. 
Increasing tobacco smoke exposure was defined by blood cotinine levels. The 
cotinine levels for evaluating the relationship between cotinine dose and risk of 
invasive CC in Study II were quartiles among control women with cotinine level 
>20ng/ml and the cut-off level for heavy smoking which was close to the median, 
102ng/ml. In the dose-response analyses the quartiles (68, 100, and 140ng/ml) of 
active smokers (>20ng/ml) were used. The dose-response relationship was tested 
by the likelihood ratio test by adding the numerical dose-response variable to the 
threshold model in which a variable indicated those, whose cotinine level was at 
least 20ng/ml. Likelihood ratio tests for linear trends in the logarithms of ORs were 
performed for increasing age at diagnosis among women with cotinine level 20-
<100ng/ml and 100ng/ml or more with and without adjustment for HPV16/18, 
HSV-2 and C. trachomatis. 
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Paper II
In this study, different cut off levels were tested, and the optimum value, cotinine 
level of 20 ng/ml, was used as the cut-off. Descriptive statistics were used to 
determine the distribution of women according to cervical SIL, age and tobacco 
exposure, and HPV positivity. Frequency tables for tobacco use (smoking and/
or chewing) among women stratified by age were produced. The effect of tobacco 
smoking and chewing on the risk of LSIL, multiple HPV infections and HSIL 
was estimated by ORs with 95% CI, derived from the logistic regression analysis. 
Because very few Ivorian women reported smoking evaluation for this habit alone 
in the logistic regression analysis was restricted to Finnish women. We conducted 
stratified analyses according to age, and the ORs were adjusted for C. trachomatis 
and HIV seropositivity (for Ivorian women). The level of statistical significance 
was p<0.05. All the statistical analyses were performed using SPSS 15.0 (SPSS Inc., 
Chicago, USA).
Paper III
Descriptive statistics were used to analyse the distribution of HPV16/18 antibody 
isotypes at baseline. McNemar’s test was used to determine the proportion of change 
over time in HPV serostatus (dichotomous outcome variable) to take into account 
the fact that the observed proportions are not independent. Seroconversion and 
persistence of HPV16/18 antibodies were assessed. Logistic regression models were 
fitted and the relative risks (estimated as OR and 95% CI) calculated using SPSS13.0 
(SPSS Inc., Chicago, USA). The model estimated the odds of seroconversion and 
the odds of maintaining persistent antibody response for HPV16/18 smokers, and 
used individuals with cotinine level less than 20 ng/ml, as the reference category. 
The ORs were adjusted for chlamydia seropositivity, a marker of high-risk sexual 
behaviour. We also conducted stratified analyses according to age. The level of 
statistical significance was p<0.05.
Paper IV
Immunogenicity analyses were based on the according-to-protocol (ATP) cohort. 
The analyses included all women who met the eligibility criteria, received the three 
vaccination shots and complied with protocol procedures. Seropositivity rates for 
HPV16 and HPV18 were calculated. P-values were calculated with Mann-Whitney 
test to compare mean absorbance of anti-HPV16 and HPV18 antibodies between 
non-smokers and smokers at each timepoint in the vaccine and control groups. 
Mean absorbance level for each antigen was reported with standard deviation 
(±Sd). Statistical analyses were performed with SPSS 16.0 (SPSS Inc., Chicago, 
USA).
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5 Results
5.1  Tobacco smoking as risk factor for invasive  
 cervical cancer (Paper I)
Effect of increasing tobacco smoke exposure on cervical cancer risk
We found that the relative risk of CC increased with increasing serum cotinine 
levels. In both Study I cohort and Study II cohort serum cotinine level ≥100ng/ml, 
which indicated heavy smoking among females was associated with an increased 
risk of invasive CC (OR = 1.7, 95% CI = 1.2–2.5; OR = 2.5, 95% CI = 2.0–3.0 
respectively). In the Study II cohort the HPV16 and 18 adjusted OR of SCC was 
markedly stronger in women with cotinine level ≥100ng/ml: 3.2 (95% CI = 2.6–
4.0) compared to women with cotinine level 20-<100ng/ml: 2.2 (95% CI = 1.7–
2.8) with only negligible overlap of the 95% CIs. Further adjustment for antibodies 
to HPV16/18, HSV-2 and C. trachomatis had no material effects on the point 
estimates. In both study cohorts, no serum cotinine levels indicative of smoking 
were associated with an excess risk of cervical adenocarcinoma.
Effect of increasing tobacco smoke exposure on cervical cancer risk among 
HPV16/18-seropositive and seronegative women
The large sample size of the Study II cohort allowed stratified analysis by HPV status 
among cases and controls. In HPV16/18-seropositives, significantly increased 
relative risk of invasive CC and of SCC were noted in women with cotinine level 
≥100ng/ml (OR = 2.1, 95% CI = 1.4–3.2, OR = 2.7, 95% CI = 1.7–4.3 respectively). 
Adjustment for antibodies to HSV-2 and C. trachomatis had no effect on the point 
estimates. Among HPV16/18-seropositive women, cotinine level 20-<100 ng/ml 
was not associated with the risk of invasive CC (OR 1.1, 95% CI = 0.7–1.8). In 
HPV16/18-seronegatives, an increased relative risk of invasive CC and SCC was 
observed both in women with cotinine level 20-<100 ng/ml and ≥100 ng/ml (Table 
5.1).
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Table 5.1 Odds ratios (OR) for risk of cervical cancer in human papillomavirus (HPV) type 16 and/or 
18 seropositive and seronegative non-smokers and smokers by increasing tobacco smoke exposure 
(defined as blood cotinine level), crude and adjusted for antibodies to herpes simplex virus type 2 (HSV-
2) and Chlamydia trachomatis (Study II)  
Cotinine 
(ng/ml)
 I n v a s i v e  c e r v i c a l  c a n c e r S q u a m o u s  c e l l  c a r c i n o m a
Crude OR     95% CI OR adj*     95% CI Crude OR     95% CI OR adj*     95% CI
HPV type 16 and/or 18 seropositives
<20
20-<100
100+
P value†
253 cases
597 controls
1
1.1  (0.7, 1.8)
2.1  (1.4, 3.2)
<0.001
247 cases
589 controls
1
1.1  (0.7, 1.8)
2.1  (1.4, 3.2)
<0.001
202 cases
460 controls
1
1.2  (0.7, 2.0)
2.7 (1.7, 4.3)
<0.001
197 cases
452 controls
1
1.1  (0.6, 2.0)
2.7  (1.7, 4.4)
<0.001
HPV type 16 and/or 18 seronegatives
<20
20-<100
100+
P value†
  335 cases
2261 controls
1
2.0  (1.6, 2.6)
2.6  (2.0, 3.4)
0.04
  330 cases
2234 controls
1
1.8  (1.4, 2.3)
2.3  (1.8, 3.0)
0.05
  243 cases
1706 controls
1
2.7  (2.0, 3.6)
3.4  (2.5, 4.5)
0.06
  240 cases
1686 controls
1
2.2  (1.7, 3.1)
2.9  (2.2, 4.0)
0.06
* OR adjusted for herpes simplex virus type 2 (HSV-2) and C. trachomatis.    
† Test for dose-response relationship (see statistical methods).
5.2  Tobacco smoking and chewing as risk   
 factors for cervical SIL (Paper II)
The proportion of women exposed to tobacco was almost ten times higher in 
Finland (36.8%) than in Côte d’Ivoire (3.7%). In Côte d’Ivoire, tobacco chewing 
was more common than tobacco smoking (2.6% versus 1.4%), and concerned 
mostly women ≥30 years of age (4.8%). 
Among tobacco chewers (Côte d’Ivoire), the risk of HSIL was five times higher 
in both young (OR = 5.5, 95% CI = 1.2–26) and older (OR = 5.5, 95% CI = 2.1–14) 
women compared to non-chewers (Table 5.2). Overall, the age-adjusted relative 
risk of cervical HSIL was also significantly increased among tobacco chewers (OR 
= 5.6, 95% CI = 2.5–12). In Finland, tobacco smokers (Finland) ≥30 years of age 
tended to have an increased risk of LSIL (OR = 2.5, 95% CI = 0.9–6.8) and HSIL 
(OR = 2.2, 95% CI = 0.5–8.7) (Table 5.2).
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Table 5.2 Age-stratified tobacco smoking/chewing-associated OR with 95% CI of low-grade 
lesions and high-grade lesions in women from Côte d’Ivoire and Finland
Variables Low-grade lesions High-grade lesions
OR (95% CI) OR (95% CI)
Côte d’Ivoire n = 165 n = 71
Age < 30 years
       Non-chewers
       Chewers
Age ≥ 30 years 
       Non-chewers
       Chewers
1.0
n.a
1.0
2.0 (0.7–5.8)
1.0
5.5
1.0
5.5
(1.2–26)
(2.1–14)
Finland n = 60 n = 28
Age < 30 years
       Non-smokers
       Smokers
Age  ≥ 30 years 
       Non-smokers
       Smokers
1.0
1.2
1.0
2.5
(0.6–2.5)
(0.9–6.8)
1.0
1.1
1.0
2.2
(0.4–3.1)
(0.5–8.7)
Further, analyses were restricted to HPV DNA-positive women to assess 
independent tobacco smoking- and chewing-associated risk of cervical LSIL and 
HSIL. Despite the small numbers of women in both settings, we found an increased, 
albeit not significant, relative risk of both LSIL and HSIL, in HPV DNA-positive 
women ≥ 30 years of age and actively exposed to tobacco through smoking (OR = 
2.2, 95% CI = 0.5–9.0 and OR = 1.8, 95% CI = 0.3–9.6 respectively) or chewing (OR 
= 2.3, 95% CI = 0.2–27 and OR = 7.3, 95% CI = 0.8–68, respectively).
5.3  Tobacco smoking and chewing as risk   
 factors for multiple HPV infections (Paper II)
Being infected with two or more HPV types (multiple HPV infections) was 
common in HPV16 and/or 18-seropositive women (60.4% in Finland and 47.2% 
in Côte d’Ivoire). Antibodies to three HPV types or more were detected in 20 of 
57 (35.1%) Ivorian and 50 of 129 (38.7%) Finnish women. The logistic regression 
analyses, however, did not show any increased risk of multiple infections among 
tobacco smokers/ chewers compared to non-smokers/chewers.
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5.4  Effect of tobacco smoking on the immune  
 response following genital HPV16/18   
 infection (Paper III)         
Effect of smoking on the development of HPV16/18 antibody response 
We assessed the effect of smoking on the development of HPV16/18 antibodies 
in initially HPV16/18 seronegative women as odds ratio. In women under 30 
years of age, only three out of 29 (10%) smokers turned positive for at least one 
HPV16/18 antibody isotype (IgG/IgA) compared to 13 of 41 (32%) non-smokers 
(OR, 0.2; 95% CI 0.0–0.9) (Table 6). Smoking-associated relative risk of HPV16/18 
seroconversion was not significantly decreased in the older age group (Table 5.3). 
There was no difference between HPV DNA positive or negative women with 
regard to the development of HPV antibodies. 
TABLE 5.3 Smoking-associated relative risk (OR and 95% CI) of developing HPV16/18 
antibodies in initially seronegative females with cytological atypia consistent with HPV 
infection 
HPV16/18 seronegative at 
baseline 
Change in serostatus   
n/Nd (%)
OR (95%CI) ORa  (95%CI)
Age < 30 years 
    IgA only
        Non-smokersb 
        Smokersc
    IgG only
        Non-smokers 
        Smokers 
   IgA and IgG
        Non-smokers 
        Smokers
7/47 (15) 
1/32 (3) 
3/37 (8) 
2/20 (10)
13/41 (32)
3/29 (10)
1
0.1 (0.0–1.5)
1
1.2 (0.1–8.2)
1
0.2 (0.0–0.9)*
1
0.2 (0.0–1.7)
1
1.1 (0.1–7.6)
1
0.2 (0.0–0.9)*
Age ≥ 30 years 
    IgA only
        Non-smokersb 
        Smokersc
    IgG only
        Non-smokers 
        Smokers 
   IgA and IgG
        Non-smokers 
        Smokers
2/16 (12)
3/8 (37)
2/26 (8)
1/20 (5)
2/15 (13)
2/7 (28)
1
4.2 (0.5–32)
1
0.6 (0.1–7.5)
1
2.6 (0.3–23)
1
4.8 (0.3–59)
1
0.7 (0.1–8.4)
1
3.2 (0.2–45)
a OR adjusted for Chlamydia trachomatis. 
b Cotinine <20ng/mL; reference group.
c Cotinine ≥20ng/mL.
d n = number of females who changed their serostatus over time.
N = total number of non smoking and smoking females in each strata. 
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Effect of smoking on the stability of HPV16/18 antibody positivity 
We assessed the smoking-associated relative risk of maintaining HPV16/18 
antibody positivity in initially HPV16/18 seropositive women. We found a 
significantly decreased risk of constant IgG antibody positivity (OR, 0.1; 95% CI 
0.0–0.8), based on one seroconversion case, among smokers. In women under 30 
years of age, 13 of 21 (62%) smokers remained IgA or/and IgG positive until the 
end of follow-up compared to 20 out of 26 (77%) non smokers (Table 5.4). Smoking 
did not materially affect the risk of IgG antibody waning in women over 30 years 
of age (Table 5.4). 
TABLE 5.4. Smoking-associated relative risk (OR and 95%CI) of persistence of HPV16/18 
antibodies in initially seropositive females with cytological atypia consistent with HPV 
infection 
HPV16/18 seropositive at 
baseline 
No change in 
serostatus n/Nd (%)
OR (95%CI) ORa  (95%CI)
Age < 30 years 
    IgA only
        Non-smokersb 
        Smokersc
    IgG only
        Non-smokers 
        Smokers 
   IgA and IgG
        Non-smokers 
        Smokers
4/10 (40)
7/11 (64)
8/12 (67)
1/8 (12)
20/26 (77)
13/21 (62)
1
2.6 (0.4–15)
1
0.1 (0.0–0.8)*
1
0.4 (0.1–1.7)
1
2.8 (0.5–17)
1
0.1 (0.0–0.8)*
1
0.4 (0.1–1.7)
Age ≥ 30 years 
    IgA only
        Non-smokersb 
        Smokersc
    IgG only
        Non-smokers 
        Smokers 
   IgA and IgG
        Non-smokers 
        Smokers
7/18 (39)
2/6 (33)
10/14 (71)
3/4 (75)
22/36 (61)
9/11 (82)
1
0.2 (0.0–6.9)
1
1.2 (0.1–15)
1
2.8 (0.5–15)
1
0.2 (0.0–6.8)
1
1.2 (0.1–15)
1
2.8 (0.5–15)
a OR adjusted for Chlamydia trachomatis. 
b Cotinine <20ng/mL; reference group.
c Cotinine ≥20ng/mL.
d n = number of females who changed their serostatus over time.
N = total number of non smoking and smoking females in each strata. 
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5.5  Effect of smoking on the immune    
 response following prophylactic HPV16/18  
 AS04-adjuvanted VLP vaccination         
A total of 216 young women from the Finnish arm were included in this pilot 
study. Out of 103 participants from the HPV16/18 group, 46.6% (48) were smokers 
compared to 56.6% (64) smokers in the control group. 
We evaluated differences in mean absorbance of anti-HPV16 and HPV18 
antibodies levels from baseline to month 7 post-vaccination. The results showed 
that the mean absorbance of anti-HPV16 antibody levels was 1.97 (±0.78) among 
non-smokers compared to 1.88 (±0.73) among smokers. The mean absorbance 
of anti-HPV18 antibody levels was 1.44 (±0.85) among nonsmokers and 1.36 
(±0.76) among smokers. The observed differences between the two groups were 
not statistically significant (Table 5.5).
TABLE 5.5 Comparison of mean absorbance level (with standard deviation (Sd)) of anti-HPV16 and HPV18 
antibodies between. Non-smokers and smokers by vaccination group
Vaccine (n = 103) Placebo (n = 113)
Non-smokers
(n = 55)*
mean (±Sd)
Smokers
(n = 48)*
mean (±Sd)
p-value† Non-smokers
(n = 49)*
mean (±Sd)
Smokers
(n = 64)*
mean (±Sd)
p-value†
HPV16
 Baseline 
 Month7
0.12 (± 0.08)
1.97 (± 0.78)
0.29 (± 0.52)
1.88 (± 0.73)
0.2
0.4
0.21 (± 0.43)
0.01 (± 0.04)
0.18 (± 0.29)
0.01 (± 0.02)
0.9
0.7
HPV18
  Baseline 
  Month7
0.07 (± 0.06)
1.44 (± 0.85)
0.18 (± 0.08)
1.36 (± 0.76)
0.1
0.6
0.10 (± 0.08)
0.01 (± 0.03)
0.10 (± 0.14)
0.01 (± 0.03)
0.8
0.7
* Nonsmokers (cotinine < 20ng/ml) and smokers (cotinine ≥ 20 ng/ml).
† p-value derived from Mann-Whitney test to evaluate mean absorbance difference between non-smokers and 
smokers.
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6 Discussion
6.1  Tobacco exposure of fertile-aged women
There are an estimated 1.3 billion adult smokers (over 15 years old) among the 
world’s six billion people. If the prevalence of tobacco use remains constant, the 
number of smokers will rise to 1.7 billion between 2020 and 2025 (Guindon and 
Boisclair 2003). Four-fifths of current smokers live in low-income or middle-
income countries.
There are important gender-specific differences in tobacco use, with global 
prevalence among males (48%) about four times higher than among females 
(10%) (Guindon and Boisclair 2003). There may, however, be considerable female 
smoking that is underreported, or unreported, because of gender norms that 
stigmatize women who smoked. Male-female differences in use are the highest 
in the Western Pacific Region and the lowest in the Americas and Europe, where 
about one quarter of women smoke (Carrao et al. 2000).
Typically, the smoking epidemic starts in most populations among men and 
higher-income groups, and later affects women and low-income groups. However, 
global male rates have peaked and have stabilized or are in slow decline, while the 
prevalence of tobacco use among women is increasing (Mackay 2001, Molarius 
et al. 2001). In fact, the historical gender differences in uptake and prevalence are 
diminishing because of the increased prevalence of smoking among adolescent 
women. Recent findings of the GYTS, the largest global survey of adolescents (aged 
13 to 15) and tobacco use, show that almost as many adolescent girls and adolescent 
boys are smoking in many parts of the world (GYTS Collaborating Group 2003). 
This is an indication of the increasing global smoking epidemic among women that 
will not peak until well into the 21st century. The prediction is that by 2025, 20% of 
the female population will be smokers, up from 12% in 2005.
Tobacco exposure is a potential environmental cofactor of CC. Therefore, the 
high frequency of tobacco smoking and chewing among women emphasizes the 
importance of assessing its impact on the development and prevention of cervical 
neoplasia. 
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6.2  Comparison of the study with findings   
 from other studies
6.2.1  Tobacco smoking is an independent risk factor for  
 cervical cancer 
Smoking was associated with an increased risk of ICC/SCC after both adjustment 
and stratification for antibodies to oncogenic HPVs. While the former could 
be confounded by misclassification bias in the serological diagnosis of hrHPV 
infection, the latter provided estimates unconfounded by persistent hrHPV 
infection as determined by serology with up tp 75% sensitivity in cases and controls 
(Kjellberg et al. 1999). The Nordic joint study (Pukkala et al. 2007) is by far the 
largest nested case-control study on risk factors of cervical cancer. Study I and Study 
II showed significant increased risk of ICC/SCC among women with cotinine level 
>100mg/ml. We found that the point estimate was lower in Study I relative to Study 
II. Women were from the same population and the same design was applied in 
both studies. Chance could be one explanation of this observed difference. Another 
explanation could be the age difference since the Study II material included older 
women compared with the Study I material. The carcinogenic effect of smoking 
is likely to increase with inceased age at diagnosis (This study, Plummer et al. 
2003) and is usually observed after a long period of exposure to tobacco smoke 
(Gunnell et al. 2006). The Study II material allowed stratified analyses to assess 
the independent role of smoking. We found a significantly increased two-fold 
excess risk of SCC, free of the non-differential residual confounding bias, among 
HPV16/18-seropositive women.
HPV VLP serology has been proven to be a specific albeit not sensitive 
marker of current and past exposure to HPV (Olsen et al. 1997). It permitted the 
delineation of HPV16/18-infected (seropositive) controls that could be compared 
with HPV16/18-infected (seropositive) cases. Our results are consistent with the 
few prospective studies that have controlled for HPV infection using high quality 
HPV assays (Plummer et al. 2003). In the UK, Deacon et al. analySed risk factors 
for progression to CIN 3 among HPV-positive women in a nested case-control 
study and reported a high risk of 2.2 (95% CI = 1.4–3.4) for ever smoking with a 
strong evidence of a dose-response effect. 
Several case-control studies (Bosch et al. 1992, Eluf-Neto et al. 1994, Chaouki 
et al. 1998, Santos et al. 2001, Hildesheim et al. 2001, Olsen et al. 1998, Rolon et 
al. 2000), including the IARC multicentre pooled analysis of 10 studies of ICC 
(Plummer et al. 2003), examined tobacco smoking as a co-factor to HPV infection 
by restricting the analysis to HPV DNA positive study participants. The results 
from these analyses showed no significant alteration in risk of CIN or CIS whether 
or not the study participants were HPV-DNA-positive. Most of these studies, 
however, tested for HPV-DNA at only one timepoint, which favoured the detection 
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of amplified HPV DNA in the cases. Furthermore, controls testing HPV-positive 
just once most likely have a transient infection. This could bias the measure for 
lifetime exposure and impact of HPV infection. Such a problem does not exist for 
HPV-seropositives since the possibility that the HPV antibodies wane over time is 
highly unlikely (af Geijersstam et al. 1998). 
The presence of tobacco carcinogens in cervical mucus has been described as 
a possible biological explanation for the epidemiological association (Simons et al. 
1995). The mechanism could involve soluble carcinogens that may have a direct 
transforming effect on squamous cervical epithelium. Some other epithelial cancers, 
those of the nasal cavity and the oesophagus, show similar differences between 
SCC and adenocarcinoma with regard to smoking and HPV (IARC 2004, Björge et 
al. 1997, Mork et al. 2001). Cigarette smoking may also exacerbate the carcinogenic 
potential of HPV specifically via inhibition of IFN-gamma and/or tumour necrosis 
factor alpha, leading to a significant inhibition of the apoptosis, which may promote 
tumor growth (Suk et al. 2001, Hussain et al. 2008). Experimental studies show 
that cigarette smoking decreases the secretion of proinflammatory cytokines (IL1, 
IL6) and suppresses IL2 and IFNγ production (Ouyang et al. 2000, Arcavi 2004), 
suggesting the possibility that cigarette smoking interacts to increase cervical 
carcinogenesis development.
6.2.2  Tobacco use (smoking/chewing) and the risk of  
 cervical SIL
The route of exposure to tobacco was different between Côte d’Ivoire and Finland 
probably due to socio-economic and cultural differences. In addition, screening for 
cervical cancer and laboratory analyses for HPV detection were performed in two 
different settings and at different times. The differences observed in the association 
of tobacco exposure and SIL by the route of tobacco exposure may, however, 
be valuable for future studies. Comparison of the separated results was feasible 
since the method used for the PAP smear test was comparable, and assessment 
and grading of cervical SIL was based on a comparable method. The lesions were 
classified into LSIL and HSIL according to the Bethesda System.
In the Côte d’Ivoire material, we identified a lack of statistically significant 
association between tobacco chewing and the risk of cervical LSIL in Ivorian 
women ≥30 years of age. Despite the low prevalence of tobacco use, our results 
showed that women who chewed tobacco had a significantly increased risk of 
cervical HSIL. To date, only one study has reported an association between tobacco 
chewing and increased risk of invasive CC in Southern India (Rajmakar et al. 
2006). Smokeless tobacco products contain and deliver high quantities of nicotine 
comparable to those typically absorbed from cigarette smoking. Moreover, these 
products are carcinogenic to humans and may result in local and systemic health 
hazards depending of the way of administration and the content of various toxic 
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products, including nicotine and tobacco-specific nitrosamines (Hoffman and 
Djordjevic 1997, Cogliano et al. 2004). 
There was an increased risk of LSIL and HSIL among Finnish women ≥ 30 
years of age who smoked tobacco. This is in line with recent studies showing that 
tobacco smoking increases the risk of cervical SIL and CC (Kjellberg et al. 2000, 
McIntyre-Seltman et al. 2005, Tolstrup et al. 2006). The point estimates, however, 
did not reach statistical significance possibly due to the small number of cases. 
The general degree of concordance between PCR and ISH is between 70 and 
90%, the main difference yielding in the sensitivity of the methods particularly 
among patients with high-grade lesions (Takuma et al. 2005, Dabie et al. 2004, 
Biedremman et al. 2004). The failure of HPV DNA hybridization studies to 
find all cervical HPV infections has been known for a long time (Leminen et al. 
1992). Possible recall bias may have led to under-reporting of smoking habits but 
it is unlikely to have affected the results as the accuracy of self-reported tobacco 
smoking habit is generally high in Finland (Vartiainen et al. 2002). 
We further restricted the analyses to HPV DNA-positive women to assess 
the independent role of tobacco smoking and chewing in cervical SIL. Although 
Ivorian and Finnish women ≥30 years of age tended to have an increased risk of LSIL 
and HSIL, we could not draw any conclusion due to the small number of women. 
Syrjänen et al. did not report an increased risk of high-grade CIN among smokers 
(Syrjänen et al. 2007). It is possible that being exposed to tobacco through smoking 
or chewing is not an independent risk factor of cervical SIL as the increased risk 
could be mediated by acquisition of hrHPV infection (Syrjänen et al. 2007). When 
restricting the analyses to women who were HPV DNA-positive, it is possible that 
we restricted attention to women whose immune response to HPV was partially 
inadequate and, in whom, therefore, smoking and chewing status could not have 
had an additional effect (Rousseau et al. 2003). 
6.2.3  Tobacco use (smoking/chewing) and the risk of  
 multiple HPV infections
There was no association between tobacco use (smoking and chewing) and the risk 
of multiple HPV infections. Kataja et al. previously reported that current smoking 
was a strong risk factor for HPV infection among Finnish women, although the 
risk did not increase in parallel with the number of cigarettes and years smoked 
(Kataja et al. 1993). More HPV types were detected in Côte d’Ivoire than in the 
Finnish study, but similar negative findings were reported among tobacco chewers 
or smokers. In Canada also, Rousseau et al. did not find an association between 
tobacco smoking and multiple HPV infections among women (Rousseau et 
al. 2003). No data have previously been published on the association between 
smoking/chewing and the risk of multiple HPV infections among women from 
less industrialized countries.
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6.2.4  Tobacco smoking impairs the immune response  
 following genital HPV16/18 infections         
To the best of our knowledge, this is the first follow-up study to relate smoking status 
based on cotinine measurements to the likelihood of developing or maintaining 
HPV16/18 antibody positivity. Young women who smoked were less likely to either 
seroconvert or maintain detectable HPV16/18 antibodies over time relative to non-
smokers.
Smoking impairs protection against and/or immunosurveillance of HPV 
infections in the uterine cervix (Syrjänen et al. 2007, Wiley et al. 2006). In a cross-
sectional study, HPV16 DNA-positive women aged 16 to 23 years who smoked 
were less likely to test positive for HPV16 IgG antibodies than non-smokers (OR, 
0.5; 95% CI 0.3–0.9) (Wiley et al. 2006). The authors suggest that there was a dose-
response relationship between smoking and anti-HPV16 antibody positivity. In 
our study the observed effect of smoking was possibly also due to the high tobacco 
exposure in young women, who tended to be heavy smokers. The follow-up time 
was not the same for all the women (range: 6–114 months) and this difference may 
have an effect on the point estimates. This is however unlikely, as there was no 
difference in the length of follow-up time between HPV-seronegative and HPV-
seropositive women at last sampling (Chi squarre (χ2) = 14.46, df = 12, p = 0.2). In 
addition, we did not observe a difference in the length of follow-up time between 
non-smokers and smokers (χ2 = 7.11, df = 12, p = 0.8).
Seroconversions against the HPV16 and 18 capsids are seen within up to a 
year following primary HPV16 and 18 infections (Wang et al. 2000, af Geijeirsstam 
et al. 1998), and IgA antibodies appear in a maximum of 20 months (Onda et al. 
2003). Our findings showed that tobacco exposure may significantly delay the 
development of HPV16/18 IgA or/and IgG antibodies in young women followed-
up for up to 5 years. It is commonly known that smokers have 10 to 20% lower 
serum antibody (IgA, IgG and IgM) levels than non-smokers. The immunoglobulin 
levels are higher among past than current smokers, and increase with duration of 
smoking cessation (Anderson et al. 1982). HPV-specific antibody response is often 
delayed but our cohort study, with a long follow-up time, allowed us to make the 
distinction between females who, eventually, had responded and those who had 
failed to respond over time. Determination of HPV16/18 IgA and IgG antibodies 
was by standard ELISA (Pagliusi et al. 2007). Serum antibodies are not affected 
by differences in blood withdrawal or specimen handling (Lehtinen et al. 2006). 
Following natural HPV infection, IgG antibodies are detectable in up to 75% of 
women (Kjellberg et al. 1999). HPV16/18 IgG seropositive women <30 years who 
smoked, had a significantly decreased likelihood of being constantly IgG antibody 
positive suggesting that smoking may promote waning of IgG antibodies over time. 
Interpreting the results was not straightforward due to the small sample size. 
Our old HPV DNA typing data probably distinguished HPV positive cases with 
high viral load only. This did not seem to have an effect as the results in DNA positive 
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and DNA negative women were comparable. However, having few strata with small 
numbers of individuals cannot exclude the possibility of change observations. 
How tobacco exposure specifically influences HPV antibody response is not 
known. HPV-infected cells may also be more susceptible to DNA damage from 
specific tobacco carcinogens (Simons et al. 1995). In addition, the fact that some 
cigarette constituents have the ability to manipulate cytokine expression in a 
manner similar to hrHPV gene expression suggests that smoking/chewing may 
enhance the ability of HPV16/18 to escape from immune surveillance (Poppe et 
al. 1995, Arcavi et al. 2004, Hussain et al. 2008). Smoking has been associated with 
persistent HPV infections (Szarewski et al. 2001) and decreased clearance of CIN 
lesions (Szarewski et al. 1996). Reduction in lesion size was highly correlated both 
with the reduction in reported amount of smoking and with the final-visit cotinine 
measurements (Szarewski et al. 1996). 
6.2.5  Tobacco smoking may not impair the immune   
 response following bivalent HPV16/18 vaccination   
This pilot study is the first to evaluate the impact of tobacco smoking, assessed 
via serum cotinine level, on the immunogenicity of bivalent HPV16/18 AS04-
adjuvanted vaccine. Young women who smoked tended to have comparable 
absorbance levels of anti-HPV16 and HPV18 antibodies to non-smokers at 7 
months-post-vaccination. 
In contrast to the often inadequate immune response following natural 
infection, a prophylactic CC vaccine should induce long-term immune response 
with high and sustained local and systemic antibody levels (Stanley et al. 2006). The 
addition of an adjuvant to a vaccine significantly increases the humoral response 
to the vaccine antigens (Giannini et al. 2006). Geometric titers (GMTs) for vaccine 
induced antibodies against HPV16 or HPV18 infections were substantially higher 
(≥11-fold) than those seen in natural HPV16 or HPV18 infections at all timepoints 
for 5.5 years (Harper et al. 2006). High seroconversion rates and strong vaccine-
induced antibody response were also evident in the interim (14.8-month) results 
of the PATRICIA study, a large phase III trial of the AS04-adjuvanted HPV16/18 
vaccine (Paavonen et al. 2007).
Our study demonstrated no statistically significant differences in vaccine-
induced humoral immune response to either HPV16 or HPV18 L1 VLP among 
young women who smoked compared to non-smokers after a 7-month follow-
up period. In a recent study investigating the effect of self-report smoking on 
HPV16/18 L1 VLP vaccine among small numbers of young women with preexisting 
HPV infections, the authors found no vaccine efficacy for viral clearance in either 
smokers (VE: -51.9, 95% CI: -136.7 to 2.5) or non-smokers (VE: 6.2, 95% CI: 
-17.1 to 24.8) after 12 months of follow-up (Hildelsheim et al. 2007). A similar 
observation has also been described for the quadrivalent HPV6/11/16/18 vaccine 
(Giuliano et al. 2007). 
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Smoking is a risk factor for oncogenic HPV infections (Syrjanen et al. 2007) 
and cervical neoplasia (Plummer et al. 2003). Tobacco smoking prevalence has 
increased considerably among women during the last decade (Mackay 2001). Long-
term immunogenicity and efficacy of HPV vaccine in preventing HPV infection 
and cervical neoplasia is unclear (Keam and Harper 2008). Although this pilot 
study was limited by the short follow-up period, the results showed that both the 
anti-HPV16 and anti HPV18 absorbance levels in HPV16/18-vaccinated smokers 
and non-smokers were comparable at month 7 post-vaccination. Comparison 
between the type-specific ELISAs determined antibody levels is, unfortunately, not 
possible. These observations, however, warrant further investigation on a larger 
number of vaccinated individuals.
6.3  Strengths and limitations of the study
Study design and bias
Case-control studies are susceptible to various forms of bias compared to cohort 
studies, the usefulness of the former in the process of causal inference is especially 
diminished. Our nested case-control design (Paper I) measured data on exposure 
and confounders before the diagnosis of the disease, thus reducing potential recall 
bias (pregnant women from FMC were a part of the material), the temporary 
ambiguity usually inherent in case-control studies. Potential recall bias may be a 
limitation in the second study (Paper II) as under-reporting of tobacco smoking 
habit among Finnish women may have distorted the true association between 
exposure and cervical HSIL. This is, however, unlikely because we found a good 
correlation between serum cotinine levels and the questionnaire data among 
Finnish women (data not shown). 
Cases and controls were drawn from the same cohort, decreasing the likelihood 
of selection bias. In Papers II and III, we performed cross-sectional studies. Despite 
the fact that this prevents us from concluding the directionality of the observed 
associations, these cross-sectional analyses allowed hypothesis generation for 
future research. 
Paper IV described the results from a random subset of a randomized 
prospective clinical intervention study (Paavonen et al. 2007). Computer-generated 
randomization was performed to avoid selection bias. Vaccine and Placebo groups 
were equally treated following a standardized written protocol in order to minimize 
bias in study management. In addition, the doubled-blinded design made it possible 
to avoid observer (ascertainment) bias. 
Misclassification of the outcome variables (Papers I and II) was unlikely as the 
diagnoses for cervical SIL, SCC or carcinoma in-situ (CIS) were reported by experts 
in cytopathology and mostly based on results from histology. Samples from cases 
(Paper I) and their controls were batched together during the laboratory analyses 
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to avoid assay-drift bias. Moreover, great care was taken to avoid differential 
measurement errors in the determination of HPV antibodies positivity or in 
cotinine detection by blinding the laboratory personnel (Papers I, II, III and IV). 
Confounding
We identified some potentiel confounders on the basis of earlier studies and 
biology. In the statistical analyses, we did not have questionnaire data on sexual 
habits, which may have resulted in slight over-estimation of the smoking-associated 
relative risks. This is however, unlikely as the point estimates were adjusted for 
antibodies to C. trachomatis, a sensitive surrogate of risk-taking sexual behaviour. 
Seropositivity to C. trachomatis shows a strong correlation with life-time number 
of sexual partners (Dillner et al. 1996). 
Validity of the method used for tobacco exposure assessment 
Complete questionnaire data on tobacco exposure history would have permitted us 
to assess the lifetime exposure to tobacco smoke, and to study the effects of smoking 
in relation to age at starting and stopping smoking. Self-report has proven to be a 
simple and powerful predictor of disease outcomes in epidemiological studies. Self-
reporting, however, underestimates the true prevalence and is inaccurate as to the 
quantity of smoking exposure (Murray et al. 1993). When smoking is a daily habit, 
the act of smoking is unlikely to be closely self-monitored. Thus, in a questionnaire, 
the respondent may be imprecise about smoking behaviours, such as number of 
cigarettes smoked per day (Benowitz 1999). On the other hand, pregnant women (a 
considerable part of our study cohorts in Studies I and II materials) tend to belittle 
their smoking habit because of health conscience (Britton et al. 2004, Burstyn et 
al. 2009).
Biochemical assessment of tobacco exposure integrates different aspects 
of the true exposure, including tobacco composition, uptake, distribution and 
individual differences in metabolism. Cotinine is a good marker of nicotine, which 
is the important carcinogen in tobacco smoke. Although serum cotinine measures 
recent exposure to tobacco smoke near the time of specimen collection, it has a 
high sensitivity and specificity for tobacco exposure and the measurement error 
is negligible compared to questionnaires (Murray et al. 1993, Boffeta et al. 2006). 
Biochemistry of identifying tobacco exposure via serum cotinine favours the 
validity of our observations. This method addresses the issue of non-differential 
recall bias. In addition, it is the inhaled dose of tobacco smoke that is directly 
related to the development of tobacco-related diseases (Pérez-Stable et al. 1995). 
Cotinine levels remain stable in frozen samples (Boffeta et al. 2006) enabling the 
identification of dose-response effects. 
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Validity of the results
The validity of the study refers to the reliability of the results. From the first to 
the fourth study, great care was taken to ensure that the results do not reflect the 
presence of bias or confounding. In biobank-based research, the process from the 
decision to take a sample from an individual to the moment the sample is safely 
placed in the biobank consists of several phases including collection of samples, 
handling and storage of samples. Failure in one of these standardized procedures 
may have significant consequences as the quality of the material stored in the 
biobank as well as conclusions and recommendations based on the analysis of such 
material may be severely affected. Established quality control of serums banks and 
cancer registries (Paper I) increases the validity of the study (Pukkala et al. 2007, 
Sjöholm et al. 2007). 
Sample size and generalisability of the results
Our Nordic joint study (Paper I) is by far the largest nested case-control study 
on risk factors for CC conducted to date. Updating the study material (Study 
I) eventually result in a sample size large enough to provide confidence in the 
estimates and therefore, ensure our ability to reveal associations. The population 
representativeness of the serum bank cohorts was recently assessed by Pukkala 
and colleagues (Pukkala et al. 2007) who found no significant difference in 
cancer incidence in the biobank cohorts involved in the present study (the Nordic 
maternity cohorts and the Janus biobank) as compared with respective national 
rates. Thus, our results can be generalized to all Nordic women, and there was no 
evidence that the odds ratios among serum banks were heterogeneous. 
In Papers II and III, the cohort participants were recruited among women 
attending routine Papanicolaou (PAP) smear. The screening activities are 
integrated in the healthcare system in Finland. In the organised programme, the 
present coverage of invitations is 90% of the target age; the participation rate is 
higher than 70% (Anttila and Nieminen 2000). In our study, all women whose PAP 
smear showed unequivocal changes of HPV infection attended the gynecological 
outpatient clinic of the Kuopio University Hospital for follow-up visits at 6-month 
intervals. There was no loss to follow-up in the Finnish study. In Cote d’Ivoire 
(Paper II) cases were drawn from the three outpatient gynecology clinics in Abidjan 
and may not accurately reflect the target population.
Assuming interval validity (Papers II to IV) and despite small sample size 
(Papers II and III), our results should also be representative of the Finnish (Papers 
II to IV) and Ivorian (Paper II) targeted populations. The study groups had similar 
physiological, behavioral, racial and cultural characteristiques than their respective 
general population. Caution must be exercised, however, in extending these results 
to other countries citizens as numerous other differences exist between nations in 
relation to genetics and lifestyle factors. 
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7 Conclusions
Tobacco smoking was associated with an increased risk of CC/SCC after adjustment 
to oncogenic HPVs. Moreover, a statistically significant 2-fold excess risk of SCC 
was found among HPV16/18-seropositive women who smoked. The risk of CC 
associated to smoking was similar in seropositive and seronegative women.
Tobacco smokers tended to have an increased risk of HSIL in women ≥30 
years of age. In less industrialized countries, which bear the heaviest burden of 
CC, exposure to tobacco is more common through chewing than smoking among 
women. Relative to non-chewers, women who chewed tobacco had a significantly 
5-fold increased risk of cervical HSIL. Although being infected with two or more 
HPV types (multiple infections) was common in HPV16 and/or HPV18-infected 
women, we did not report an increased risk of multiple HPV infections among 
tobacco smokers/chewers compared to non-smokers/non-chewers.
We showed that following natural HPV infection, young women who smoked 
were less likely to either seroconvert or maintain detectable HPV16/18 antibodies 
over time than non-smokers.
We found that following AS04-adjuvanted HPV16/18 L1 VLP vaccination, 
young women who smoked or did not smoke had comparable short-term 
HPV16/18 serum antibody response at 7 months post vaccination. 
We conclude that tobacco smoking is an independent risk factor for CC in 
women infected with oncogenic HPVs. In addition, the results suggest that smoking 
may induce impaired antibody response to oncogenic HPVs but not immediately 
after prophylactic HPV vaccination in young women. The evidence discussed in 
this dissertation supports comprehensive primary prevention initiatives against 
causes of CC, with a call for strengthening efforts to prevent tobacco smoking and 
chewing exposures among women.
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